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I. INTRODUCTION 
Cancer is a main cause of disease provoking high morbidity and mortality worldwide. In 2012, 
8.2 million cancer-related deaths and estimated 14.1 million new cases arose compared to 7.6 
million and 12.7 million in 2008, respectively [1, 2], and the incidence of new cases is even 
predicted to increase to 22.2 million by 2030 [3]. Treatment options including chemotherapy, 
radiotherapy, surgery, immunotherapy or hormone therapy often have an insufficient success 
rate and side effects, therapy resistance and metastasis formation implicate an urgent 
improvement and further research in cancer therapy. Therefore, two fields of interest, tumor 
targeted gene delivery and chemoresistance, have been focused and are illustrated in the 
following.          
 
1. Polymeric nucleic acid carriers for tumor targeted gene delivery 
1.1. Nucleic acid therapy 
Treatment of diseases caused by genetic alteration is made possible via gene therapy. Medicinal 
nucleic acids offer the possibility to manipulate gene expression in a controlled manner [4] in 
order to treat genetically-based diseases like monogenetic, infectious, cardiovascular, 
neurological, ocular and inflammatory disorders or cancer [5], whereas viral vectors have 
mainly been used as delivery vehicles. These agents can induce gene expression by plasmid 
DNA (pDNA) resulting in a “gain of function” or trigger gene silencing by antisense 
oligonucleotides or synthetic small interfering RNA (siRNA) mediating a “loss of function” 
[4]. Cancer diseases have been focused for gene therapy [5] whereas the major paths to achieve 
therapeutic effects are silencing of genes responsible for tumor growth, metastasis or cell 
survival and introduction of genes hampering cellular growth by apoptosis [6, 7]. Remarkable 
success has already been achieved with gene therapy of patients suffering from hemophilia B 
[8] or severe combined immunodeficiency (SCID) [9], yet it’s still limited therapeutic use so 
far is based on the inefficient delivery of nucleic acids [10]. 
Application of naked nucleic acids without a carrier is only rarely effective such as upon 
intramuscular vaccination or hydrodynamic delivery of naked pDNA [11, 12]. After systemic 
application nucleic acids face many bottlenecks on the way towards their site of action. In the 
extracellular environment they have to be protected against enzymatic degradation by nucleases 
[13], complement activation and unspecific interactions with blood components and matrix 
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[14]. Once reaching the target tissue nucleic acids have to overcome the cell membrane being 
internalized into the endosomes [15]. Finally intracellular, they have to escape from the 
endosomes into the cytosol since these will change later into lysosomes where nucleic acid 
digestion takes place. siRNA is already on target in the cytosol by incorporation into the RNA-
induced silencing complex (RISC) and hence, after separation of the strands, suppresses the 
gene expression by degrading or blocking translation of target mRNA [16]. For pDNA, further 
transport to the nucleus is required to mediate gene expression (Figure 1). This illustrates 
another bottleneck of plasmid delivery because the cellular actin cytoskeleton hinders the 
translocation of pDNA to the perinuclear region [17, 18]. Moreover, passive nuclear uptake can 
only occur during cell division in proliferating cells when the nuclear membrane is degraded. 
In non-dividing cells for particles larger than 9 nm, which therefore cannot pass the membrane 
via passive diffusion, an active nuclear import through the nuclear pore complex (NPC) is 
necessary which can be achieved with the help of short peptide sequences, called nuclear 
localization signals (NLS) [19, 20].  
 
 
1.2. Carrier systems for gene delivery 
Carriers for gene delivery can generally be classified into viral and non-viral vectors [21]. Viral 
vectors randomly integrate into the genome and can therefore be used as delivery agents for 
therapeutic genes. However, their very high transfection efficacy is clouded by safety issues 
limiting therapeutic use. Viruses can have immunogenic and inflammatory effects hampering 
Figure 1: Steps of siRNA and pDNA delivery. Polyplexes are taken up into the tumor cell 
via endocytosis. After escaping the endosome siRNA is released into the cytosol and 
incorporated into the RISC complex. For successful gene expression from pDNA further 
transport to the perinuclear region and nuclear import of pDNA is essential. 
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repeated applications. Besides, limited payload capacity and difficulties to produce them in high 
amounts are further disadvantages of viruses [22]. To conquer these limitations synthetic non-
viral carriers have attracted attention as a promising alternative. Carriers synthesized from 
various natural and synthetic molecules can be tailored to specific needs and mimic functions 
and surface domains of viruses to avoid unspecific biological interactions and mediate specific 
targeting of host cells [23]. Especially liposomes [24] and polymers [22, 25] have emerged as 
promising candidates for gene delivery. The negative charge of the nucleic acid backbone 
allows electrostatic interactions with the cationic liposomes or polymers which results in 
condensed complexes also called “lipoplexes” and “polyplexes” [26]. As a result of neutralizing 
the negative charges, DNA collapses into smaller structures than its free form which is up to 
µm large in size [27]. The condensation leads to small nanoparticles susceptible for endocytosis 
[28]. The most widely studied cationic polymers are polypeptides such as polylysine (PLL) [29] 
or polyethylenimine (PEI) [30, 31] and dendrimers like polyamidoamines (PAMAM) or 
polypropylenimine (PPI) [32]. Due to its high transfection efficacy based on its good endosomal 
buffering capacity to enhance endosomal escape, linear polyethylenimine (LPEI) has emerged 
as gold standard in gene delivery [33]. However, critical drawbacks of these polymers remain 
such as toxic side effects due to their high molecular weight and cationic charge and a lack of 
biodegradability [34-36]. Therefore, functional domains, e.g. for shielding, targeting and 
enhancing endosomal escape can be added to increase safety and transfection efficacy of the 
polyplexes [23].   
1.3. Prospects of endosomal escape 
Endosomal escape is a major obstacle in gene delivery. After internalization into endosomes 
polyplexes have to escape from them since these get acidified and change into lysosomes where 
degradation takes place. A way to overcome endosomal entrapment is the incorporation of lytic 
lipid domains such as oleic acids [37, 38], stearic acids [39-41] or cholesterol [42, 43] into the 
polymeric carrier resulting in hydrophobic interactions between endosomal membrane and 
polyplexes. Another approach is the incorporation of endosomolytic peptides like 
hemagglutinin HA2 deriving from the influenza virus [44] or melittin [45]. Cationic polymers 
such as PEI possess an intrinsic endosomolytic activity [46]. Their unprotonated amine groups 
can buffer protons which results in chloride and water accumulation in the endosomes leading 
to osmotic pressure. Triggered by the concomitant increase of positive polymer charges in the 
endosomes, vesicles lyse consequently and release their content into the cytosol providing an 
escape mechanism for polyplexes [47], also called “proton sponge effect” [48] with regard to 
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the absorption of protons like a sponge. Histidines are known to increase this effect because 
they become cationized upon protonation of their imidazole rings, thus enhancing endosomal 
buffering capacity. Therefore, the incorporation of histidines as functional domains can 
improve endosomal escape and hence transfection efficacy [49].    
1.4. Targeting of polyplexes towards their site of action  
To mediate specific cellular uptake polyplexes have to be directed towards the target tissue. 
This field of interest can be categorized into active and passive targeting. Passive targeting is 
occurring due to the enhanced permeability and retention (EPR) effect [50]. This effect is based 
on the limited blood supply of rapidly growing tumors and the resulting intense angiogenesis 
leading to fenestrated and leaky blood vessels with reduced lymphatic drainage [51]. Upon 
systemic administration small molecules can diffuse nonspecifically out of the blood stream 
into all tissues, whereas macromolecules only pass the leaky endothelium of the tumor and 
accumulate there due to impaired lymphatic drainage [50, 52]. The other strategy to address 
tumors is active targeting which is enabled by diverse expression levels of surface receptors in 
cancer tissues. Commonly addressed receptors are the transferrin receptor [53-56], integrin 
receptor [57-59], epidermal growth factor (EGF) receptor [60-63] or the folic acid (FA) receptor 
[64, 65]. Classes of targeting ligands that are able to bind to receptors are antibodies and their 
fragments [66, 67], glycoproteins [68], peptides [57, 69, 70] and small molecules [71] amongst 
others. The receptor reviewed in this thesis belongs to the cell surface receptor tyrosine kinases 
family - the hepatocyte growth factor receptor (HGFR) also named c-Met. It is predominantly 
expressed in epithelial cells [72] and overexpressed in cancer cells, epithelial-derived tumors 
and in stromal and interstitial cell-derived tumors like fibro- and other sarcoma types [73]. Upon 
binding of the natural ligand - hepatocyte growth factor (HGF) - to the receptor mitogenesis, 
motogenesis and morphogenesis are stimulated, and oncogenesis, tumor progression and 
aggressive cellular invasiveness are promoted. Possibilities to set anticancer drugs at this 
signaling pathway are antagonizing of ligand/receptor interactions, inhibition of tyrosine kinase 
activity and blocking of intracellular interactions [74]. Taking advantage of the c-Met/HGFR 
overexpression has mostly been limited for in vivo imaging and conjugation of an anti-c-Met 
antibody fragment to doxorubicin so far [75-78] but it has not been applied for targeted gene 
delivery.                   
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1.5. Dendrimers 
Compared to the gold standard in gene delivery, LPEI, with its inherent heterogeneity and 
cytotoxicity thus limiting its use, dendrimers can be denoted by an advance towards more 
defined polymers. Their central core molecule is an origin for highly branched symmetrical 
arms which are covalently coupled. Each additional layer (generation) is added stepwise 
resulting in a low polydispersity index and well defined size and structure [32]. As transfection 
efficacy and cytotoxicity of both PAMAM and PPI dendrimers still can be improved several 
modifications have been carried out for gene delivery such as targeting with folate [79], 
transferrin [80] and numerous other ligands, hydrophobic modifications with fatty acids [81, 
82] or phenylalanine [83], cationization with arginine [84, 85] or histidinylation [86] for 
improved endosomal escape. Increased molecular weight (Mw) can on the one hand enhance 
transfection efficacy of the polymers based on low in vivo polyplex stability for low Mw 
compounds [87], but can on the other hand lead to increased cytotoxicity [88]. It is known that 
environment-triggered biodegradation can solve this problem [27, 89, 90]. The dendrimer 
reviewed in this thesis was hence built modifying the core of a PPI of the second generation 
(PPI G2) which has a lower cytotoxicity and moderate pDNA transfer efficacy [91]. An analog 
molecule to PEI based on the artificial amino acid succinoyl-tetraethylene pentamine (Stp) [92] 
consisting of increasing numbers of Stp units was attached as octamers via disulfide linkages 
to generate safe carriers with higher Mw (Figure 2).  
 
Figure 2: Schematic overview of PPI G2 core linked via disulfide linkages to Stp 
oligomers. Biodegradation takes place in the reducing cytosol environment.   
+ 
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1.6. Precise sequence-defined polymers 
Another approach to develop a precise, monodisperse and multifunctional carrier system was 
illustrated by Hartmann et al. They designed well-defined polycationic conjugates with 
precisely positioned functional moieties for tailor-made features via solid-phase synthesis [93]. 
Schaffert et al. developed the method further by introducing novel building blocks [92]. A 
library of polymers with different topologies and functional domains was hence synthesized for 
gene delivery [94-97]. Polymers reviewed in this thesis were synthesized according to this 
method based on a polycationic backbone consisting of repeating units of the artificial amino 
acids Stp or succinoyl-pentaethylene hexamine (Sph) as building block. Cysteines were 
incorporated for redox-sensitive polyplex stabilization resulting from disulfide formation and 
histidines for increased endosomal buffering capacity. Polyethylene glycol (PEG) was attached 
for surface shielding from unwanted interactions with blood components and the ligand cMBP2 
was attached for targeted polymers (Scheme 1). 
 
2. Chemoresistance 
Development of chemoresistance is a major drawback in the successful treatment of cancer 
patients hampering the efficacy of chemotherapeutic drugs. Treatment failure in more than 90% 
of metastatic cancer patients is believed to be induced by reason of chemoresistance [98]. 
Circumvention of drug resistance would therefore have a high impact on clinical outcome and 
survival of patients. On the one hand pharmacological factors such as inefficient tumor drug 
concentration and on the other hand cellular factors can account for the development of 
chemoresistance. Manifestation of resistance can be classified into intrinsic, hence existing 
before the first therapy, and acquired resistance which is developed during chemotherapeutic 
treatment. The diverse mechanisms leading to cellular resistance include increased drug efflux 
through ABC (ATP-binding cassette) drug transporters, alterations in drug targets and changes 
in cellular response such as enhanced repair mechanisms of DNA, stress toleration and evasion 
of apoptosis pathways [98-100]. Another important mechanism of resistance formation to 
chemotherapeutic drugs are cancer stem cells (CSCs). These cells within a tumor are protected 
from chemotherapeutic treatment by ABC transporters as well as to self-renew after 
chemotherapy and are therefore responsible for relapse [101, 102].  
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2.1. Metastasis formation and impact of miRNAs 
Metastases at distant sites in the body are difficult to treat effectively and remain a major cause 
of death. Tumor spreading is propelled by a process called epithelial to mesenchymal transition 
(EMT), a developmental program leading to invasive and migratory properties of cancer cells 
which dissociate from the primary tumor, invade and exit blood vessels and subsequently cause 
metastases at distant tissues. For this purpose they undergo mesenchymal to epithelial transition 
(MET) and reshape into cells with epithelial-like properties [103-105]. 
microRNAs (miRNAs), small non-coding RNAs of about 22 nucleotide sequences regulating 
gene expression [106], are a class of molecules that are often up- or downregulated in several 
types of cancer [107-109]. Based on their target genes they can be classified into tumor 
suppressor and oncogenic miRNAs [108, 110]. They are known to play a role in the acquisition 
of chemoresistance as they can modulate the sensitivity of cancer cells upon chemotherapy 
[111-114]. Additionally, miR-200c has been proposed to regulate EMT through targeting 
repressors of E-cadherin, an epithelial marker [115, 116], resulting in an increased E-cadherin 
expression and low migratory capability of cancer cells hence displaying epithelial-like 
properties [117, 118]. The inhibition of EMT by miR-200c reduces cancer cell migration and 
invasion thus hampering metastasis formation [119-121]. On the contrary, a loss of miR-200c 
at the beginning of metastasis induces EMT which results in low E-cadherin and high vimentin 
levels hence displaying mesenchymal-like properties with an increased migratory capability of 
cancer cells [115-118, 120].  
CSCs show characteristics of cells which have undergone EMT [103] and have also been 
proposed to be involved in tumor invasion and metastasis formation [101]. Hence, they display 
crucial targets in cancer therapy. 
2.2. Salinomycin 
The potassium-ionophore salinomycin (Figure 3) was recently found to selectively target CSCs 
and to reduce the proportion of CSCs in contrast to the classical chemotherapeutic drug 
paclitaxel [122]. Salinomycin is a polyether antibiotic isolated from the bacteria Streptomyces 
albus and has been used as an anticoccidial drug in poultry and other livestock [123, 124]. Its 
anti-cancer mechanisms in diverse cancer types known so far include induction of apoptosis 
and cell death, interference with ABC transporters and cytoplasmic or mitochondrial K+ efflux, 
inhibition of Wnt signaling and oxidative phosphorylation, and differentiation of CSCs [125]. 
Besides, salinomycin has been proposed to reduce malignant traits in colorectal cancer cells 
[126] and to inhibit growth and migration of prostate cancer by inducing oxidative stress [127]. 
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Of note, a few clinical pilot studies have shown a partial clinical regression of pretreated 
therapy-resistant cancers upon treatment with salinomycin [125] which is therefore very 
promising for further in vivo investigations. 
 
  
2.3. Overcoming multiple drug resistance with nanocarriers 
Multiple drug resistance (MDR) in cancer is one of the main reasons for chemotherapy failure. 
MDR is characterized by a broad cross-resistance of cancer cells to structurally different 
chemotherapeutics after acquiring resistance to an individual drug [128]. Potential mechanisms 
of MDR in chemotherapy include overexpression of ABC transporters which results in 
increased drug efflux, CSCs, miRNA regulation, hypoxia induction, efficient repair of DNA 
damage and epigenetic regulation such as DNA methylation and histone modification. One of 
the main mediators of MDR represents the overexpression of ABC drug transporters like the 
well-known permeability glycoprotein (P-glycoprotein), MDR-associated protein1 (MRP1) 
and breast cancer resistance protein (BCRP) [129]. Several approaches to circumvent MDR 
such as co-application of P-glycoprotein inhibitors (e.g. verapamil) display poor selectivity for 
cancer cells hence mediating low therapy efficacy and toxic side effects [130].  
Nanoparticle-based drug delivery, a highly investigated field, offers beneficial options 
concerning specific targeting of cancer cells, increased drug efficacy, lower drug toxicity and 
improved solubility and stability. Moreover, the intracellular drug concentration in cancer cells 
is increased because nanosized particles can utilize the EPR effect [130]. Nanoparticles can be 
Figure 3: Structural formula of salinomycin. 
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categorized into (1) organic, (2) inorganic and (3) hybrid systems. Organic material systems 
(e.g. liposomes, emulsions, albumins, etc.) are situated already in clinical stage for cancer 
chemotherapy as delivery agents for original drugs through improvement of their bioavailability 
and targeting efficacy [131-133]. Inorganic nanobiomaterials (e.g. magnetic [134], metallic 
[135], carbon-based nanoparticles [136]) have gained increased attention due to their high 
thermal/chemical stability, good biocompatibility, resistance to corrosion and easy endowment 
with structural features and specific properties such as mesoporosity. Yet, a crucial issue to 
consider remains the low degradability of inorganic materials of which silica is one of the most 
biocompatible materials due to its endogenous occurrence in bones [131]. A core-shell silica 
nanoparticle encapsulating a fluorescent dye has already been approved by the FDA for a 
human stage I clinical trial for molecular imaging of cancer [137]. Organic-inorganic hybrid 
nanobiomaterials combine advantages of both organic and inorganic materials and can therefore 
have unique characteristics such as controlled drug release, co-delivery of multiple drugs, etc. 
[138, 139].  
Mesoporous silica nanoparticles (MSN) have been highly investigated for improving 
chemotherapeutic efficacy, overcoming MDR and inhibiting metastasis formation. In terms of 
circumventing MDR several strategies have been recognized [140]. Multiple drugs can be co-
loaded into MSN such as a classical chemotherapeutic drug together with an ABC transporter 
inhibitor (e.g. surfactants [141] or siRNA for gene silencing [142, 143]). Moreover, drug efflux 
can be circumvented by direct intranuclear drug delivery of MSN (e.g. using a cell-penetrating 
TAT peptide [144]) whereby ABC transporter inhibitors are no longer required. Additionally, 
a multi-modal combinatorial therapy with MSN combining chemo- with radiotherapy (e.g. 
MSN encapsulating chemo- and radiotherapeutic agents simultaneously [145]) illustrates 
another promising strategy.    
2.4. Mesoporous silica nanoparticles with pH-responsive polymer coating 
MSN display high loading capacity and enable a broad range of inner and outer surface 
modifications [146]. Several strategies to prevent premature release of MSN exist such as 
covalent attachment of cargo inside the mesopores [147] or capping of the whole particle [148-
151]. Methods to promote drug release are e.g. light irradiation [147, 152, 153] and change of 
reduction potential [154], temperature [155], or pH [148, 156]. Polymers are highly attractive 
to coat MSN due to their biocompatibility and tunable properties [157, 158]. pH-responsive 
polymer coatings take advantage of the pH change during endocytosis as trigger for drug 
release. The ability of effective pH-responsive MSN coating using polymers was already 
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demonstrated for poly(acrylic acid) [159] and poly(2-(diethylamino)ethyl methacrylate) [160]. 
Furthermore, poly(2-vinylpyridine) (PVP) was applied for pH-sensitive functionalization based 
on the pronounced transition between hydrophobicity and hydrophilicity upon de-/protonation 
[161]. MSN reviewed in this chapter were functionalized with a pH-responsive cap system 
using the polymer PVP. At low pH the polymer is protonated and in a hydrophilic state enabling 
drug molecules to diffuse into and out of MSN. At pH values of 5.5 or higher the polymer is 
started to be deprotonated, thus converting into a hydrophobic state which results in a collapse 
of the polymer onto the surface preventing release of the drug molecules (Figure 4). Besides, 
PEG was attached to the ends of the PVP cap to increase colloidal stability. Furthermore, it 
enables covalent attachment of a wide variety of functionalities at the outer periphery of the 
PEG shell such as targeting ligands or dyes. The pores of MSN are about 4 nm and the average 
particle diameter is 90 nm for unfunctionalized MSN and 200 nm for PVP/PEG modified MSN 
(Stefan Niedermayer, PhD thesis 2014).     
 
 
 
 
 
 
Figure 4: Concept of the pH-responsive polymer coating. The pores can be reversibly 
uncovered through changes in water solubility of the polymer upon de-/protonation.   
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3. Aims of the thesis 
3.1. Polymeric nucleic acid carriers 
The aim of this part of the thesis was to evaluate three synthesized polymeric systems, 
polypropylenimine (PPI) dendrimers, histidine-containing four-arm polymers and c-Met-
directed structures for their gene transfer efficacy in vivo. Evaluation should be done in 
xenograft mouse tumor models by measurement of gene expression after local or systemic 
administration of pDNA polyplexes.  
First, biodegradable polymers with increased molecular weight (Mw) should be compared to 
lower Mw PPI dendrimers as high Mw is generally associated with enhanced transfection 
efficacy.  
Secondly, four-arm polymers containing histidines should be compared to alanine control 
polymers because the incorporation of histidines results in enhanced endosomal buffer capacity 
facilitating endosomal escape, a major bottleneck in gene delivery.  
Thirdly, polymers targeted with the c-Met receptor-binding ligand cMBP2 should be evaluated 
and compared to an alanine control polymer upon local and systemic administration. 
Additionally, the impact of an enhanced shielding, an increased polycationic part of the polymer 
and co-addition of non-shielded polymers to improve systemic delivery were to be assessed. 
3.2. Chemoresistance 
The acquisition of chemoresistance upon treatment with classical anti-cancer drugs and 
formation of metastasis to secondary tissues still display major drawbacks for the cure of cancer 
patients. In this part of the thesis two approaches to circumvent these obstacles should be 
investigated.  
First, the polyether antibiotic drug salinomycin, which has been demonstrated to selectively 
target cancer stem cells and which has therefore been promising to improve cancer therapy, 
should be analyzed concerning its effect on tumor growth and migration. In a next step, if 
effective, it was purposed to evaluate its potential as an additive compound to a classical 
chemotherapeutic drug.  
Secondly, loading of chemotherapeutic drugs into nanoparticles has raised hope for improving 
chemotherapeutic efficacy, overcoming drug resistance and metastasis formation. Since the 
controlled release displays a critical obstacle in delivery of drugs, synthesized pH-responsive 
coated mesoporous nanoparticles should be evaluated in terms of biodistribution, 
biocompatibility and tumor targeting in vivo.
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II. MATERIALS AND METHODS 
1. Materials 
1.1. Cell culture 
Neuro2A     ATCC (Wesel, Germany) 
HuH7 cells     NIBIO (Osaka, Japan) (formerly HSRRB) 
4T1-Luc cells     Caliper Life Sciences (Alameda, CA, USA) 
MDA MB 231 cells    ATCC (Wesel, Germany) 
KB cells     ATCC (Wesel, Germany) 
DMEM 1 g/l Glucose medium  Invitrogen (Karlsruhe, Germany) 
DMEM 4.5 g/l Glucose medium  Invitrogen (Karlsruhe, Germany) 
Ham`s F12 medium    Invitrogen (Karlsruhe, Germany) 
RPMI 1640 medium    Invitrogen (Karlsruhe, Germany) 
FCS (fetal calf serum)   Invitrogen (Karlsruhe, Germany) 
L-alanyl-L-glutamine    Biochrom (Berlin, Germany) 
PBS (phosphate buffered saline)  Biochrom (Berlin, Germany) 
Trypsin EDTA solution   Biochrom (Berlin, Germany) 
Cell culture plates and flasks   TPP (Trasadingen, Switzerland) 
1.2. In vivo experiments 
Isoflurane CP®    CP-Pharma (Burgdorf, Germany) 
Bepanthen®     Bayer Vital GmbH (Leverkusen, Germany) 
Na-luciferin     Promega (Mannheim, Germany) 
Syringes, needles    BD Medical (Heidelberg, Germany) 
Multivette (serum tubes)   Sarstedt (Nümbrecht, Germany) 
NaCl 0.9 % (isotonic sodiumchloride)  Braun Melsungen AG (Melsungen, Germany) 
HBG (HEPES buffered 5% glucose,  HEPES: Biomol (Hamburg, Germany) 
pH 7.4) Glucose-monohydrate: Merck (Darmstadt, 
Germany) 
Matrigel® Matrix (356231)   Fisher Scientific GmbH (Schwerte, Germany) 
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1.3. Laboratory animals 
1.3.1. NMRI nude mice 
Female Rj:NMRI-Foxn1nu/Foxn1nu mice were purchased from Janvier (Le Genest-St-Isle, 
France). This outbred mouse strain has a mutation in the gene Foxn1 which is affecting thymus 
development and hair follicle keratinization. Due to the absence of T-lymphocytes mice are 
immunodeficient and hence used for xenotransplantation. Other immune system cells like B-
cells, NK-cells and Macrophages are present. Nudeness enables an ideal experimental setup for 
bioimaging studies.    
1.3.2. BALB/c mice 
Female BALB/cByJRj mice were purchased from Janvier (Le Genest-St-Isle, France). These 
small inbred albino mice are immunocompetent and therefore used in a syngeneic 4T1-tumor 
model. Furthermore they were used as sentinel animals for health monitoring of the animal 
facility.  
1.3.3. Housing 
Laboratory mice were housed inside an air-conditioned room in individually ventilated cages 
(IVC type ІІ long, Tecniplast) within a 12 h-day-and-night cycle. The maximum occupancy 
was 5 animals per cage with autoclaved food and water ad libitum and weekly change of the 
bedding. Mice were purchased at an age of 5 weeks and allowed an acclimatization time of at 
least one week to adapt to the housing conditions. Health monitoring of the animal facility was 
conducted quarterly according to FELASA recommendations. 
All animal experiments were performed according to the guidelines of the German law for 
protection of animal life. They were approved by the local ethics committee.  
1.4. Ex vivo experiments 
Cell lysis buffer    Promega (Mannheim, Germany) 
Lysing Matrix D    MP Biomedicals (Strasbourg, France) 
Luciferase assay buffer   Promega (Mannheim, Germany) 
Mayer´s haematoxylin solution  Sigma-Aldrich (Steinheim, Germany) 
Eosin Y     Sigma-Aldrich (Steinheim, Germany) 
Tissue-Tek® Cryomold   Sakura Finetek (Heppenheim, Germany) 
Tissue-Tek® O.C.T. Compound  Sakura Finetek (Heppenheim, Germany) 
Tissue-Tek® Mega-Cassette   Sakura Finetek (Heppenheim, Germany) 
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SuperFrost Ultra Plus® slides  Menzel GmbH (Braunschweig, Germany) 
DAPI      Sigma-Aldrich (Steinheim, Germany) 
1.5. Polymers 
PPI conjugates were synthesized by Edith Salcher (PhD thesis 2013, LMU).  
 
Conjugate 
(Polymer ID) 
Sequence Abbreviation 
536 PPI-(C-C-Stp5)8 PPI-Stp5 
PPI G2 PPI - 
 
Three-arm, four-arm and cMBP2-targeted polymers were synthesized by Ulrich Lächelt and 
Dongsheng He (PhD students, LMU Pharmaceutical Biotechnology). 
 
Conjugate 
(Polymer ID) 
Sequence Topology 
608 AK[AK(A-Sph-A-Sph-A-Sph-AC)2]2 Four-arm; w/o His 
606 AK[HK(H-Sph-H-Sph-H-Sph-HC)2]2 Four-arm; with His 
442 K[dPEG24-HK[H-(Stp-H)4-C]2]-cMBP2 Two-arm; 1 PEG 
440 A-dPEG24-HK[H-(Stp-H)4-C]2 Two-arm; 1 PEG 
694 K[(dPEG24)2-HK[H-(Stp-H)4-C]2]-cMBP2 Two-arm; 2 PEG 
616 A-(dPEG24)2-HK[H-(Stp-H)4-C]2 Two-arm; 2 PEG 
677 K[dPEG24-K(HK(H-(Sph-H)3-C)2)2]-cMBP2 Four-arm; 1 PEG 
678 A-dPEG24-K[HK(H-(Sph-H)3-C)2]2 Four-arm; 1 PEG 
689 C-H-(Stp-H)3-K-[(H-Stp)3-H-C]2 Three-arm; with His 
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608/SPH-AC      І) 
 
 
 
606/SPH-HC      ІІ)                     
 
     
 
442/cMBP2-1PEG/     Ш) 
440/Ala-1PEG    
 
 
694/cMBP2-2PEG/     ІV) 
616/Ala-2PEG 
 
    
677/cMBP2-1PEG/     V)   
678/Ala-1PEG   
    
 
689        VI) 
 
 
 
 
 
Scheme 1: Schematic overview of the synthesized polymers. A: alanine; K: lysine; H: 
histidine and C: cysteine represent the α-amino acids in a one-letter-code; L: targeting ligand 
cMBP2 or the corresponding control alanine. 
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1.6. pDNA 
pCMVLuc     Plasmid Factory (Bielefeld, Germany) 
1.7. Chemotherapeutics 
Doxorubicin hydrochloride (D1515)  Sigma-Aldrich (Schnelldorf, Germany) 
Salinomycin (S6201)    Sigma-Aldrich (Schnelldorf, Germany) 
1.8. Mesoporous silica nanoparticles 
Mesoporous silica nanoparticles (MSN) were synthesized by Stefan Niedermayer (PhD thesis 
2014, LMU) and Stefan Datz (PhD student, LMU Physical Chemistry), both from the group of 
Prof. Dr. Thomas Bein. 
The following types of MSN were applied: 
 
MSN-NH2 
MSN-PVP-PEG-NH2 
MSN-PVP-PEG-NH2-FA 
 
Cy7 (Cyanine 7 NHS-ester/maleimide) Lumiprobe, (Hannover, Germany) 
ATTO 633 maleimide   ATTO-TEC GmbH (Siegen, Germany) 
Calcein     Sigma-Aldrich (Schnelldorf, Germany) 
1.9. Instruments 
FastPrep®-24 instrument   MP Biomedicals (Solon, USA) 
Centro LB 960 luminometer Berthold Technologies (Bad Wildbad, Germany) 
Cordless animal shaver GT 420 ISIS Aesculap Suhl GmbH (Suhl, Germany) 
Caliper DIGI-Met    Preisser (Gammertingen, Germany) 
IVIS Lumina     Caliper Life Science (Rüsselsheim, Germany) 
Tissue embedding Leica EG1150 Leica Microsystems GmbH (Wetzlar, Germany) 
Microtome Leica RM2265 Leica Microsystems GmbH (Wetzlar, Germany) 
Paraffin floating bath MEDAX GmbH & Co. KG (Neumünster, 
Germany) 
Cryostat Leica CM3050 S Leica Microsystems GmbH (Wetzlar, Germany) 
Olympus BX41    Olympus (Hamburg, Germany) 
Zeiss Cell Observer SD   Carl Zeiss AG (Göttingen, Germany) 
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1.10. Software 
Graph Pad Prism 5 software   Graph Pad Software (San Diego, USA) 
Living Image 3.2    Caliper Life Science (Rüsselsheim, Germany) 
 
2. Methods 
2.1. Cell culture 
Mouse neuroblastoma cells (Neuro2A) were cultured in Dulbecco´s modified Eagle´s medium 
(DMEM 1 g/l Glucose). Human hepatocellular carcinoma cells (Huh7) were grown in a 1:1 
mixture of Dulbecco´s modified Eagle´s medium and Ham´s F12 medium. Stably luciferase 
expressing murine breast adenocarcinoma cells (4T1-Luc) were cultured in RPMI 1640 
medium. Human breast adenocarcinoma cells (MDA-MB-231) were grown in Dulbecco´s 
modified Eagle´s medium (DMEM 4.5 g/l Glucose) and human cervix carcinoma cells (KB) 
were cultured in RPMI 1640 folate free medium at 37 °C in 5 % CO2 humidified atmosphere. 
All media were supplemented with 10 % fetal calf serum (FCS) and 4 mM stable glutamine. 
2.2. In vivo experiments 
Laboratory mice were purchased at an age of five weeks and experiments were carried out at 
6-8 weeks old mice. Tumor cells for all in vivo experiments were cultured as described above. 
In order to harvest the cells, they were peeled off using trypsin/EDTA solution which was 
subsequently inactivated with medium. Cells were centrifuged at 1000 rpm for 5 minutes and 
the cell pellet was resuspended in PBS at the desired final concentration. For experiments using 
Matrigel® matrix for propagation of human tumors, cells were also resuspended in PBS but 
diluted with Matrigel® (1:1) prior to injection. Subcutaneous inoculations of cells were carried 
out with a 1 ml syringe with a 27 gauge needle. Intraperitoneal applications required a 1 ml 
syringe with a 29 gauge needle and for intravenous and intratumoral injections an insulin 
syringe (29 gauge) was used. Tumor growth and body weight were monitored every second or 
third day. Inhalation anesthesia was performed with 2.5 % isoflurane in oxygen and eye lube 
(Bepanthen®) was used to prevent drying out the cornea. 
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2.2.1. Systemic luciferase gene transfer with polypropylenimine 
dendrimers 
Neuro2A cells (5 x 106 per mouse) in 150 µl PBS were injected subcutaneously into the left 
flank of 8 female NMRI nude mice. On day 12, after tumor cell inoculation, mice were divided 
into two groups (n = 4) and polyplex solution was injected into the tail vein. The polyplex 
solution contained 60 µg pCMVLuc (around 2.5 µg/g body weight) complexed with either 
536/PPI-Stp5 or PPI G2 at N/P (protonatable nitrogens of oligomer/phosphate in the nucleic 
acid backbone) ratio of 12 in a total volume of 200 µl HBG. After 48 hours all mice were 
euthanized by cervical dislocation, tumors and organs (lung and liver) were collected and 
homogenized in cell culture lysis buffer using a tissue and cell homogenizer (FastPrep®-24). 
The samples were subsequently centrifuged at 3000 g at 4 °C for 10 minutes to separate 
insoluble cell components. Luciferase activity was determined in the supernatant using a Centro 
LB 960 luminometer. 
2.2.2. Systemic luciferase gene transfer with four-arm polymers with and 
without histidines 
Neuro2A cells (5 x 106 per mouse) in 150 µl PBS were injected subcutaneously into the left 
flank of 10 female NMRI nude mice. On day 12, after tumor cell inoculation, mice were divided 
into two groups (n = 5) and injected with polyplex solution into the tail vein. The polyplex 
solution contained 60 µg pCMVLuc (around 2.5 µg/g body weight) complexed with either 
608/SPH-AC or 606/SPH-HC at N/P 12 in a total volume of 200 µl HBG. After 48 hours all 
mice were euthanized by cervical dislocation and tumors and organs (lung, liver, spleen, kidney 
and heart) were collected. Sample preparation was carried out as stated above.  
2.2.3. Intratumoral luciferase gene transfer with two-arm c-Met-directed 
polymers 
Huh7 cells (5 x 106 per mouse) in 150 µl PBS were inoculated subcutaneously into the left flank 
of 20 female NMRI nude mice. Approximately 12 days after tumor cell implantation, when 
tumors reached the adequate size (about 500-700 mm3), mice were divided into four groups (n 
= 5), anesthetized with isoflurane and injected with polyplex solution intratumorally. The 
polyplex solution contained 50 µg pCMVLuc (around 2.5 µg/g body weight) complexed with 
either two-arm polymer 442/cMBP2-1PEG, 440/Ala-1PEG, 694/cMBP2-2PEG or 616/Ala-
2PEG at N/P 12 in a total volume of 60 µl HBG. After 24 hours all mice were euthanized by 
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cervical dislocation and tumors were dissected. Sample preparation was carried out as stated 
above. 
2.2.4. Fluorescence imaging after local polyplex administration 
Huh7 cells (5 x 106 per mouse) in 150 µl PBS were inoculated subcutaneously into the left flank 
of 4 female NMRI nude mice. Two weeks after tumor cell implantation mice were divided into 
two groups (n = 2), anesthetized with isoflurane and injected with polyplex solution 
intratumorally. The polyplex solution contained 50 µg pCMVLuc (20 % labeled with Cy7) 
complexed with either targeted (442/cMBP2-1PEG) or untargeted (440/Ala-1PEG) polymers 
at N/P 12 in a total volume of 60 µl HBG. Near infrared (NIR) fluorescence was measured by 
a charge-coupled device (CCD) camera immediately after polyplex injection and repeated after 
0.25, 0.5, 4, 48 and 72 hours. Efficiency of the fluorescence signals was presented for evaluation 
with equalized color bar scales for each group. Pictures were taken with medium binning and 
an exposure time of 30 seconds.  
2.2.5. Systemic luciferase gene transfer of initial and modified c-Met-
directed polymers 
Huh7 cells (5 x 106 per mouse) in 150 µl PBS were inoculated subcutaneously into the left flank 
of 40 female NMRI nude mice. Approximately 12 days after tumor cell implantation, when 
tumors reached the adequate size (about 500-700 mm3), mice were divided into eight groups (n 
= 5) and polyplex solution was injected into the tail vein. The polyplex solution contained 80 
µg pCMVLuc (around 4 µg/g body weight) at N/P 12 in a total volume of 200 µl HBG. For this 
purpose initial two-arm polymers 442/cMBP2-1PEG and 440/Ala-1PEG; four-arm polymers 
677/cMBP2-1PEG and 678/Ala-1PEG and mixtures of the initial two-arm polymers with three-
arm 689 or four-arm 606/SPH-HC were used. After 48 hours all mice were euthanized by 
cervical dislocation and tumors and organs were dissected. Sample preparation was carried out 
as stated above. 
Quantification by real-time PCR (RT-PCR) was carried out to determine residual amounts of 
pDNA in tumors. Polyplex solution was injected as described above and mice (n = 3) were 
sacrificed after 4 hours. Total DNA was isolated according to manufacturer's instructions using 
peqGOLD guanidinisothiocynate/phenol method (Peqlab, Germany). Quantitative RT-PCR 
was then performed on a LightCycler 480 system (Roche) using UPL Probe #84 (Roche) and 
Probes Master (Roche). The following primer sequences were used: reverse primer 5'-CCC 
CGT AGA AAA GAT CAA AGG-3' and forward primer 5'-GCT GGT AGC GGT GGT TTT 
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T-3'. The pDNA dilution series were run in parallel to allow the absolute quantification. RT-
PCR was performed by Petra Kos (PhD student, LMU Pharmaceutical Biotechnology).  
2.2.6. Preliminary dose-finding of doxorubicin 
Regarding the effect of doxorubicin on tumor growth and metastasis of 4T1-Luc tumors 
different dosages were evaluated. Mice were locally shaved and 4T1-Luc cells (1 x 106 per 
mouse) in 50 µl PBS were inoculated into the left next to the last caudal mammary fat pad of 
12 female BALB/c mice. 24 hours later mice were randomly divided into four groups (n = 3) 
and treated with doxorubicin (2 mg/kg, 5 mg/kg and 8 mg/kg) or control (NaCl 0.9 %) every 
six days for three times. Body weight and tumor growth were determined every second or third 
day during the experiment. On day 18, after tumor cell inoculation, two mice treated with 8 
mg/kg doxorubicin had to be euthanized due to severe weight loss (the third mouse of this group 
already on day 7). Before euthanasia bioluminescence imaging was performed as described for 
the other groups. On day 22 the remaining three groups were anesthetized with 2.5 % isoflurane 
in oxygen and 6 mg Na-luciferin in 100 µl PBS were injected intraperitoneally. After 15 minutes 
of distribution all mice were euthanized through cervical dislocation, lungs were dissected and 
bioluminescence imaging was performed by a CCD camera (IVIS Lumina system) with Living 
Image software 3.2. Photon emission of isolated lungs was measured and images were 
interpreted with equalized color bar scales. Regions of Interest (ROIs) were defined for 
quantification and were calculated as photons/second/cm2 (total flux/area). Bioluminescence 
imaging was performed with an exposure time of 10 seconds and medium binning. 
2.2.7. Effect of salinomycin on tumor growth rate 
For evaluating the effect of salinomycin on tumor growth the syngeneic 4T1-Luc mouse model 
was used in BALB/c mice. Mice were locally shaved and 4T1-Luc cells (2 x 106 per mouse) in 
150 µl PBS were inoculated subcutaneously into the left flank of 18 female BALB/c mice. 
Three days after tumor cell injection mice were randomly divided into one treatment (n = 9) 
and one control group (n = 9). Mice were treated with 5 mg/kg salinomycin (2 mg/ml in 
dimethyl sulfoxide (DMSO) stock solution was diluted in phosphate buffered saline), control 
mice were treated with DMSO in phosphate buffered saline. Treatment was carried out on day 
3, 6, 8, 10, 13 and 15 after tumor cell inoculation. Tumor growth was measured on day 2, 4, 6, 
9, 13 and 17, after tumor cell inoculation, with a caliper using formula a x b2/2 (a = longest side 
of the tumor; b = widest side vertical to a). Over a period of 17 days the average tumor volumes 
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of the two groups were compared. On day 17 all mice were euthanized through cervical 
dislocation and tumors were harvested. 
2.2.8. Effect of salinomycin on tumor colonization and migration 
The effect of salinomycin on tumor colonization was tested in the syngeneic 4T1-Luc mouse 
model. 20 female BALB/c mice were randomly divided into two groups (treatment and control) 
and 4T1-Luc cells (1 x 105 per mouse) were injected intravenously via tail vein. 24 and 0.5 
hours before tumor cell inoculation the treatment group was premedicated intraperitoneally 
with 5 mg/kg salinomycin (2 mg/ml in DMSO stock solution was diluted in phosphate buffered 
saline) and the control group with DMSO in phosphate buffered saline. Treatment was repeated 
on day 3, 6 and 9, after tumor cell injection, and tumor colonization was monitored via 
bioluminescence imaging on day 3, 8 and 13. For this purpose, mice were anesthetized with 2.5 
% isoflurane in oxygen and 6 mg Na-luciferin in 100 µl PBS were injected intraperitoneally. 
After 15 minutes of distribution bioluminescence imaging of anesthetized mice was performed 
by a CCD camera (IVIS Lumina system) with Living Image software 3.2. Lungs were defined 
as ROI for quantification and photon emission was calculated as photons/second/cm2 (total 
flux/area). Images were interpreted with equalized color bar scales. Bioluminescence imaging 
was performed with an exposure time of 5 seconds and medium binning. On day 13 mice were 
euthanized after bioluminescence imaging and organs (lung, brain, spleen, kidneys and liver) 
were dissected for subsequent ex vivo luciferase measurements. Sample preparation was carried 
out as stated above. One mouse of the control group had to be sacrificed already earlier due to 
severe medical condition. 
2.2.9. Combinatorial treatment of doxorubicin and salinomycin 
Regarding the combinatorial effect on tumor growth and metastasis, treatment with doxorubicin 
and salinomycin was evaluated within one trial in the syngeneic 4T1-Luc mouse model. 4T1-
Luc cells (1 x 106 per mouse) in 50 µl PBS were inoculated into the left next to last caudal 
mammary fat pad of 40 female BALB/c mice. 24 hours later mice were randomly divided into 
four groups (n = 10). The first, the control group, received weekly intravenous injections of 0.9 
% NaCl and intraperitoneal injections of DMSO in phosphate buffered saline at the same 
intervals as the group treated with salinomycin. The second group was weekly treated 
intravenously with 3.5 mg/kg doxorubicin for three weeks, the third group received 5 mg/kg 
salinomycin intraperitoneally twice a week on day 4, 6, 11, 13, 18 and 20 and the fourth group 
was treated with 3.5 mg/kg doxorubicin plus 5 mg/kg salinomycin at the same intervals as 
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indicated above. Body weight and tumor growth were determined every second or third day. 
On day 21, after tumor cell inoculation, mice were anesthetized with 2.5 % isoflurane in oxygen 
and 6 mg Na-luciferin in 100 µl PBS were injected intraperitoneally. After 15 minutes of 
distribution all mice were euthanized through cervical dislocation, lungs were dissected and 
bioluminescence imaging was performed by a CCD camera (IVIS Lumina system) with Living 
Image software 3.2. Photon emission of the isolated lungs was measured and images were 
interpreted with equalized color bar scales. ROIs were defined for quantification and were 
calculated as photons/second/cm2 (total flux/area). Bioluminescence imaging was performed 
with an exposure time of 10 seconds and medium binning. Tumors and organs were harvested. 
2.2.10. Systemic distribution of mesoporous nanoparticles (MSN) 
Tumor free NMRI nude mice were anesthetized with 2.5 % isoflurane in oxygen and injected 
intravenously into the tail vein with a 100 µg (5 mg/kg) dose of Cy7-labeled (covalently linked 
to amino groups on the surface of MSN) or Cy7-loaded (covalently linked to the inner surface 
of MSN) functionalized MSN-PVP-PEG-NH2-FA or unfunctionalized MSN-NH2 dispersed in 
100 µl HEPES buffered glucose (HBG). NIR fluorescence was measured by a CCD camera 
immediately after injection and was repeated after 0.25, 0.5, 1, 4, 24 and 48 hours. Each trial 
was performed with three animals per group. Efficiency of the fluorescence signals was 
presented for evaluation with equalized color bar scales for each group. Pictures were taken 
with medium binning and an exposure time of 30 seconds. 
2.2.11. Clinical chemistry and histopathology after systemic injection of 
MSN 
Tumor free NMRI nude mice (n = 9) were sacrificed through cervical dislocation 48 hours after 
intravenous injection of pure HBG or a 100 µg (5 mg/kg) dose of functionalized MSN-PVP-
PEG-NH2-FA or unfunctionalized MSN-NH2 dispersed in 100 µl HBG. Blood was collected in 
serum tubes and clinical chemistry parameters (alanine transaminase/aspartate transaminase, 
creatinine levels and blood urea nitrogen) were analyzed. Organs were dissected, fixed in 
formalin and embedded into paraffin. Organs were cut with a microtome into 4.5 µm slices and 
stained with eosin and haematoxylin. Results were documented using an Olympus BX41 
microscope.  
For biocompatibility experiments with increased dosages of MSN, tumor free NMRI nude mice 
(n = 8) were divided into four groups and injected intravenously with a 1.6 mg (80 mg/kg) or 2 
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mg (100 mg/kg) dose of functionalized (MSN-PVP-PEG-NH2-FA) and unfunctionalized 
(MSN-NH2) particles. Intravenous administration of MSN was repeated after seven days. 
2.2.12. Tumor-targeting after systemic administration of MSN 
MDA MB 231 cells (5 x 106 per mouse) resuspended in PBS but diluted with Matrigel® (1:1) 
prior to injection were inoculated subcutaneously into the left flank of 9 female NMRI nude 
mice. On day 42, after tumor cell implantation, mice were randomly divided into three groups 
(n = 3) and injected intravenously via tail vein with a 100 µg (5 mg/kg) dose of untargeted 
(MSN-PVP-PEG-NH2) and folic acid (FA) targeted (MSN-PVP-PEG-NH2-FA) particles 
loaded with fluorescent dyes (calcein and covalently linked ATTO 633) dispersed in 100 µl 
HBG or pure HBG. Mice were sacrificed by cervical dislocation 3 hours after injection, tumors 
and organs (liver, spleen, kidneys and lungs) were harvested, embedded into TissueTek™ and 
stored immediately at -20 °C. For preparation of cryosections with a thickness of 5 μm a Leica 
cryotom was used. Cryosections were dried and fixed with 4 % paraformaldehyde. Nuclei were 
counterstained with DAPI and results were documented via spinning disc microscopy with a 
Zeiss Cell Observer SD microscope. 
2.2.13. Retention of MSN in subcutaneous tumors 
KB cells (5 x 106 per mouse) in 150 µl PBS were inoculated subcutaneously into the nape of 6 
female NMRI nude mice. On day 14, after tumor cell implantation, mice were randomly divided 
into two groups (n = 3) and injected intratumorally with a 100 µg (5 mg/kg) dose of Cy7-labeled 
functionalized FA targeted (MSN-PVP-PEG-NH2-FA) and untargeted (MSN-PVP-PEG-NH2) 
MSN dispersed in 50 µl HBG into anesthetized mice. NIR fluorescence was measured by a 
CCD camera immediately after injection and repeated after 0.25, 0.5, 1, 4, 24, 48, 72, 96, 120, 
144 and 168 hours. Fluorescence signals of the tumors were counted as total flux/area and 
normalized to 0 minutes. Efficiency of the fluorescent signals was presented for evaluation with 
equalized color bar scales for each group. Pictures were taken with medium binning and an 
exposure time of 30 seconds.   
2.3. Statistical analysis 
Results are expressed as mean value ± S.E.M if not indicated elsewise. Statistical analysis was 
performed with t-test using GraphPadPrism™. P-values < 0.05 were considered as significant.
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III. RESULTS 
1. Polymeric nucleic acid carriers for tumor targeted gene delivery 
Three different polymeric systems, polypropylenimine dendrimers, histidine-containing four-
arm polymers and c-Met-directed structures were analyzed for gene transfer in vivo. 
Experiments were performed with Petra Kos (PhD thesis 2014, LMU) in NMRI nude mice.  
1.1. In vivo characterization of polypropylenimine dendrimers 
The polypropylenimine (PPI) core was modified with increasing units (1 - 5 units) of small 
sequence-defined oligomers based on the oligoamino acid succinoyl-tetraethylene pentamine 
(Stp). Unmodified low toxic PPI of the second generation (PPI G2) served as a control. pDNA 
encoding for firefly luciferase was used for transfections to allow measurement of transgene 
expression via bioluminescence. First, in vitro transfection efficacy of all synthesized 
polypropylenimine dendrimers was screened on Neuro2A cells (murine neuroblastoma). Figure 
5 shows the efficacy of dendrimers containing increasing numbers of Stp units. Especially PPI 
conjugates with 3 to 5 repeating Stp units revealed the highest luciferase gene expression with 
similar levels as the “gold standard” LPEI. In comparison, unmodified PPI G2 showed only 
moderate efficacy (around 1 log unit below LPEI). According to these results and to its good 
pDNA binding ability, low cytotoxicity and high endosomal buffering capacity (Petra Kos, PhD 
thesis 2014, LMU), 536/PPI-Stp5 was chosen for further in vivo characterization.      
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To analyze and compare the gene transfer efficacy in vivo, 536/PPI-Stp5 and PPI G2 pDNA 
polyplexes at N/P 12 containing 60 µg pCMVLuc were injected intravenously in a total volume 
of 200 µl HBG into the tail vain of mice bearing subcutaneous Neuro2A tumors. After 48 hours 
mice were sacrificed, tumors and organs (lung and liver) were collected, homogenized in cell 
culture lysis buffer and subsequently centrifuged. Luciferase activity determined in the 
supernatant revealed a significant gene expression in tumor, lung and liver (Figure 6). 536/PPI-
Stp5 polyplexes led to a significantly higher gene transfer in Neuro2A tumors compared to PPI 
G2 polyplexes. In contrast, 536/PPI-Stp5 polyplexes showed lower luciferase expression in 
lung and liver than PPI G2 polyplexes.    
    
Figure 5: Luciferase gene transfer of polypropylenimine dendrimers with increasing 
numbers of Stp units at different N/P ratios. The luciferase activity in the cell lysates was 
analyzed 24 hours after transfection. LPEI was used as a positive control, HBG buffer treated 
cells served as a background. Data are presented as mean values ± S.D. out of quintuplicate. 
Data were generated by Petra Kos (PhD thesis 2014, LMU). 
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Figure 6: Luciferase gene expression. 48 hours after intravenous administration of PPI G2 
and 536/PPI-Stp5 pDNA polyplexes into Neuro2A tumor bearing mice luciferase gene 
expression was measured. A) Tumor, B) Liver, C) Lung. Lysis buffer RLU (relative light unit) 
values were subtracted. Liver weight was around 1.5 g, lung weight around 90 mg and 
Neuro2A tumor weight 433 ± 134 mg. Represented is the mean ± S.E.M. of four mice per 
group. Significance of the results was evaluated by t-test (*p<0.05; **p<0.01). 
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1.2. Influence of histidines on transgene expression in vivo 
A critical requirement for efficient gene transfer after cellular uptake remains the escape of 
polyplexes from endolysosomes. Incorporation of histidines increases the total endolysosomal 
buffer capacity. Precise four-arm polymers based on the building block succinoyl-
pentaethylene hexamine (Sph) containing histidines (606/Sph-HC) and the histidine-free analog 
(608/Sph-AC) were thus compared with their luciferase pDNA transfection efficacy. Scheme 
1-І+II gives an overview over the structures of the synthesized polymers. First, in vitro 
transfection studies were carried out on Neuro2A tumor cells revealing enhanced gene transfer 
with histidinylated structures (Figure 7).  
 
 
 
 
 
 
 
 
Subsequently, mice bearing subcutaneous Neuro2A tumors were injected with 606/Sph-HC or 
608/Sph-AC pDNA polyplexes at N/P 12 containing 60 µg pCMVLuc intravenously into the 
tail vein in a total volume of 200 µl HBG. After 48 hours mice were sacrificed, tumors and 
organs (lung, liver, kidney, spleen and heart) were collected, homogenized in cell culture lysis 
buffer and subsequently centrifuged. Luciferase activity was determined in the supernatant. 
Notably, histidine containing 606/Sph-HC polyplexes mediated highest luciferase transgene 
expression in the tumor tissue (approximately 20000-fold above lysis buffer background) with 
tumor expression levels over 32-fold improved over the histidine-free analog 608/Sph-HC 
(Figure 8). Both formulations showed low expression levels in lung and heart (approximately 
Figure 7: Luciferase pDNA transfection of Neuro2A cells. Comparison of four-arm Sph 
based polymers containing optionally histidines. The luciferase activity in the cell lysates was 
analyzed 24 hours after transfection. LPEI was used as a positive control, HBG buffer treated 
cells served as a background. Data are presented as mean values ± S.D. out of quintuplicate. 
Data were generated by Petra Kos (PhD thesis 2014, LMU).  
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600-800-fold above background) and high transgene expression levels in liver (approximately 
3600-7500-fold above background). Furthermore, the histidine containing 606/Sph-HC 
formulation also induced considerable gene transfer in spleen and kidney (approximately 2300-
2500-fold above background) in contrast to its histidine-free analog 608/Sph-AC. In summary, 
606/Sph-HC showed 32-fold enhanced activity over 608/Sph-AC in tumor, 2-fold in liver, 4-
fold in spleen and 5-fold in kidney. Aside from these findings, both polyplexes were tolerated 
quite well and did not mediate any visual sign of acute toxicity.   
 
 
1.3. Targeted c-Met-directed polyplexes for efficient gene transfer in vivo 
The goal of active targeting is to enhance specific uptake of particles into cancer cells. Receptor 
targeted gene delivery with various targeting ligands is enabled through the upregulation of 
surface receptors in cancer tissues. In the following experiments, the c-Met receptor-binding 
ligand cMBP2 was evaluated concerning in vivo transfection efficacy and compared to a non-
targeted alanine control polymer. Petra Kos (PhD thesis 2014, LMU) already demonstrated the 
successful in vitro gene transfer and the absence of receptor activation of cMBP2-targeted 
polymers. c-Met/HGFR overexpressing hepatocellular carcinoma tumors (Huh7) were utilized 
as xenograft tumor mouse model in NMRI nude mice.   
 
Figure 8: Luciferase gene expression. 48 hours after intravenous administration of pDNA 
polyplexes with four-arm Sph based polymers containing histidines (606/Sph-HC) or alanines 
(608/Sph-AC) into Neuro2A tumor bearing mice luciferase gene expression was measured. 
Lysis buffer RLU (relative light unit) values were subtracted. Represented is the mean ± S.E.M. 
of five mice per group. 
tumor lung liver spleen kidney heart
105
106
107 608/Sph-AC
606/Sph-HC
R
L
U
/o
rg
a
n
  III. Results 
29 
 
1.3.1. Intratumoral gene transfer after local administration of c-Met-
directed polyplexes 
The histidine-enriched two-arm polymer 442/cMBP2-1PEG with one PEG24 (polyethylene 
glycol) unit (Scheme 1-III) yielded the most auspicious in vitro gene transfer (Petra Kos, PhD 
thesis 2014, LMU) and was therefore selected first for subsequent in vivo experiments. 
Although attachment of a second PEG24 unit had not shown a beneficial effect in vitro, a 
shielded analog (694/cMBP2-2PEG) with two PEG24 units (Scheme 1-IV) was evaluated at the 
same time, as an additional PEG24 chain might be beneficial in vivo concerning polyplex 
biodistribution and ligand accessibility. Anesthetized mice bearing subcutaneous Huh7 tumors 
were injected intratumorally with polyplexes containing 50 µg pCMVLuc complexed with 
either 442/cMBP2-1PEG, 440/Ala-1PEG, 694/cMBP2-2PEG or 616/Ala-2PEG at N/P 12. 
After 24 hours mice were sacrificed, tumors were collected, homogenized in cell culture lysis 
buffer and subsequently centrifuged. Luciferase activity was determined in the supernatant and 
revealed a significant cMBP2 tumor targeting effect of 442/cMBP2-1PEG polyplexes, with a 
15-fold higher gene expression than the alanine control polyplexes 440/Ala-1PEG (Figure 9-
A). A minor gene expression was displayed for polymers with an extra PEG24 chain but still 
revealed a cMBP2 targeting effect of polymer 694/cMBP2-2PEG (7-fold higher expression) 
compared to its alanine control 616/Ala-2PEG.  
Due to the fact that luciferase gene transfer studies do not allow a quantification of total plasmid 
amount in tumors after local administration of polyplexes, quantitative polymerase chain 
reaction (qPCR) was performed to confirm a cMBP2 targeting effect. According to the 
luciferase gene transfer experiments, the highest retention of plasmid concentration in the tumor 
was achieved with the initial cMBP2-targeted two-arm polymer with only one PEG24 chain 
(442/cMBP2-1PEG). Compared to its non-targeted alanine control (440/Ala-1PEG) the amount 
of plasmid in tumor was almost 10-fold higher and to the cMBP2-targeted two PEG24 unit 
containing polyplexes (694/cMBP2-2PEG) more than 3-fold higher (Figure 9-B). 
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1.3.2. Intratumoral polyplex retention 
Based on the first promising intratumoral gene transfer studies which showed a major targeting 
effect for the two-arm cMBP2 polymer with one PEG24 unit (442/cMPB2-1PEG) compared to 
the polymer with 2 PEG24 units, it was subsequently chosen for further in vivo studies. 
To analyze the functionality of the cMBP2-targeted carrier system, its retention effect was 
compared to its untargeted alanine control polymer (440/Ala-1PEG). For this purpose, 
polyplexes with Cy7-labeled pDNA were injected into subcutaneous Huh7 tumors of 
anesthetized mice. Analysis was done via near infrared (NIR) imaging of the mice immediately 
after polyplex injection and repeated after 0.25, 0.5, 4, 48 and 72 hours. Figure 10 shows one 
representative mouse per group. 
 
Figure 9: In vivo transfection efficacy. A) Luciferase gene expression 24 hours after 
intratumoral administration of cMBP2-targeted and alanine control pDNA polyplexes with 
either one or two PEG24 chains into Huh7 tumor bearing mice. Lysis buffer RLU (relative light 
unit) values were subtracted. Luciferase gene expression is presented as RLU/tumor. The 
weights of the Huh7 tumors were 387 ± 146 mg. Represented is the mean ± S.E.M. of five mice 
per group. B) Quantification of luciferase pDNA detected in tumors 24 hours after intratumoral 
administration of pDNA polyplexes determined with qPCR. Represented is the mean ± S.E.M. 
of four mice per group. qPCR was performed by Petra Kos (PhD student, LMU Pharmaceutical 
Biotechnology). 
Significance of the results was evaluated by t-test (*p<0.05; **p<0.01; ***p<0.001).  
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For two-arm targeted (442/cMBP2-1PEG) particles a strong fluorescent signal in tumor was 
visible over 72 hours, being the highest 30 minutes after polyplex injection probably due to the 
distribution of a high amount of particles in the tumor tissue. In comparison, the non-targeted 
alanine control particles (440/Ala-1PEG) display no Cy7 signal increase in tumor but a 
decreasing signal after 4 hours representing a weaker retention in the tumor tissue and a shorter 
persistency than the targeted particles. Importantly, for non-targeted Ala-1PEG particles an 
immediate liver signal (cranial of the tumor) was observed whereas in case of the targeted 
cMBP2 particles a liver signal appeared only 30 minutes after polyplex administration. 
1.3.3. Systemic gene transfer of c-Met-directed polyplexes after 
intravenous administration 
By reason of the preliminary intratumoral studies which displayed the efficacy of the targeting 
ligand cMBP2, targeted polyplexes were further analyzed for their systemic delivery potential 
in vivo because of the high impact of this administration route.    
Figure 10: Retention of polyplexes in the tumor tissue. Untargeted polyplexes (top) and 
targeted polyplexes (bottom) were injected intratumorally and NIR imaging was performed 
immediately and repeated after 0.25, 0.5, 4, 48 and 72 hours (h). One representative mouse per 
group is shown. The color scale (efficiency) had a minimum of 2.2e-8 and a maximum of  
1.0e-7 fluorescent photons/incident excitation photon.    
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1.3.3.1. Initial two-arm polymer   
Since the so far tested initial targeted two-arm polymer with one PEG24 unit displayed the 
highest transfection efficacy in the intratumoral gene transfer studies, this polymer was 
subsequently applied for systemic delivery experiments. Two-arm targeted (442/cMBP2-
1PEG) and untargeted control polyplexes (440/Ala-1PEG) containing an increased amount of 
pDNA (80 µg pDNA compared to 50 µg in the intratumoral experiments) were injected 
intravenously into the tail vein of mice bearing subcutaneous Huh7 tumors. Mice were 
sacrificed two days after administration, tumors and organs (lung and liver) were collected, 
homogenized in cell culture lysis buffer and subsequently centrifuged. Luciferase activity 
determined in the supernatant displayed moderate expression levels in tumor and organs but 
did not reveal any significant targeting effect of the cMBP2-targeted polyplexes over the 
untargeted control polyplexes (Figure 11). 
     
1.3.3.2. Polymers with additional polycationic arms 
Due to insufficient gene transfer efficacy of the initial two-arm polymer further improvements 
on polymeric structure of this carrier system were realized. Intratumoral gene transfer 
experiments already revealed that an increase to an even 2-fold higher PEG content was rather 
unfavorable hence the opposite direction was taken towards an enhanced dimension of the 
Figure 11: Gene transfer after intravenous administration of the initial two-arm polymer. 
Gene expression in tumor, lung and liver 48 hours after intravenous administration of 
442/cMBP2-1PEG and 440/Ala-1PEG pDNA polyplexes into Huh7 tumor bearing mice. 
Luciferase gene expression is presented as relative light units per organ or tumor (RLU/organ). 
Lysis buffer RLU values were subtracted. Represented is the mean ± S.E.M. of five mice per 
group.   
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polycationic part of the polymers. Although implicating no advantage in vitro (Petra Kos, PhD 
thesis 2014, LMU), polyplexes formed with PEGylated four-arm polymer 677/cMBP2-1PEG 
and the untargeted alanine control 678/Ala-1PEG (Scheme 1-V) were applied for systemic gene 
transfer studies because they still might be favorable in vivo. Polyplexes containing 80 µg 
pDNA were injected intravenously into the tail vein of mice bearing subcutaneous Huh7 
tumors. Mice were sacrificed two days after administration, tumors and organs (lung and liver) 
were collected, homogenized in cell culture lysis buffer and subsequently centrifuged. 
Luciferase activity of these polymers with a higher cationic trait determined in the supernatant 
displayed a significant cMBP2 targeting-dependent luciferase expression in tumor despite only 
moderate expression levels similar to liver and lung (Figure 12).    
 
1.3.3.3. Co-addition of a non-shielded three-arm polymer to the initial two-arm 
polymer 
To further improve transfection efficacy and targeting effect of cMBP2 upon systemic 
administration, an alternative approach to optimize the polymers was considered. Therefore, a 
novel three-arm polymer (689) without PEG shielding was synthesized (Scheme 1-VI). Due to 
disulfide-crosslinking of terminal cysteines of the targeted two-arm cMBP2 polymer and the 
Figure 12: Gene transfer after intravenous administration of polymers with a higher 
amount of cationic charges. Gene expression in tumor, lung and liver 48 hours after 
intravenous administration of 677/cMBP2-1PEG and alanine control 678/Ala-1PEG pDNA 
polyplexes into Huh7 tumor bearing mice. Luciferase gene expression is presented as relative 
light units per organ or tumor (RLU/organ). Lysis buffer RLU values were subtracted. Liver 
weight was around 1.5 g, lung weight around 210 mg and Huh7 tumor weight 282 ± 197 mg. 
Represented is the mean ± S.E.M. of five mice per group. Significance of the results was 
evaluated by t-test (*p<0.05).   
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three-arm polymer stable polyplexes can be formed. Hereupon, this new polymer was mixed in 
a ratio of 30:70 with the initial cMBP2-targeted two-arm polymer (442/cMBP2-1PEG) to reach 
an N/P ratio of 12. Polyplexes formed with targeted bi-polymeric particles (442/cMBP2-1PEG 
+ 689) or the corresponding untargeted alanine control (440/Ala-1PEG + 689) were applied for 
systemic gene transfer studies in mice. Polyplexes containing 80 µg pDNA were injected 
intravenously into the tail vein of mice bearing subcutaneous Huh7 tumors. Mice were 
sacrificed two days after administration, tumors and organs (lung and liver) were collected, 
homogenized in cell culture lysis buffer and subsequently centrifuged. In contrast to mono-
polymer 442/cMBP2-1PEG polyplexes (Figure 11), luciferase activity determined in the 
supernatant revealed a highly increased expression in tumor (Figure 13) for the cMBP2-targeted 
bi-polymeric particles (442/cMBP2-1PEG + 689). The tumor signal of the non-targeted alanine 
control polyplexes (440/Ala-1PEG + 689) was exceeded by 22-fold and of the cMBP2-targeted 
mono-oligomer polyplexes (442/cMBP2-1PEG) by 35-fold (Figure 11). The luciferase 
expression in the organs lung and liver was up to 50-fold lower than in tumor (Figure 13-A). 
The amount of pDNA accumulating in tumor 4 hours after intravenous injection was 
determined by qPCR. Administration of cMBP2-targeted polyplexes resulted in an increased 
pDNA amount in tumor compared to the alanine analogs confirming the cMBP2 targeting 
effect. According to the luciferase gene transfer experiments, the highest pDNA retention was 
observed with cMBP2-targeted bi-polymeric particles (442/cMBP2-1PEG + 689) 
outperforming their alanine analogs 30-fold (Figure 13-B).             
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1.3.3.4. Co-addition of a non-shielded four-arm polymer to the initial two-arm 
polymer 
To examine whether this beneficial effect after co-adding polymer 689 is specific or it can be 
achieved by the addition of any non-shielded polymer a different combination was investigated 
in their systemic transfection efficacy. Instead of three-arm polymer 689 a four-arm polymer 
with Sph building blocks (Scheme 1-II) was mixed in a ratio of 30:70 with the initial cMBP2-
targeted two-arm polymer (442/cMBP2-1PEG) to reach an N/P ratio of 12. Polyplexes formed 
with cMBP2-targeted bi-polymeric particles (442/cMBP2-1PEG + 606) or the corresponding 
untargeted alanine control (440/Ala-1PEG + 606) were applied for systemic gene transfer 
studies in mice. Polyplexes containing 80 µg pDNA were injected intravenously into the tail 
vein of mice bearing subcutaneous Huh7 tumors. Mice were sacrificed 48 hours after 
administration, tumors and organs (lung and liver) were collected, homogenized in cell culture 
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Figure 13: Gene transfer after intravenous administration of bi-polymeric particles. A) 
Luciferase gene expression in tumor, lung and liver 48 hours after intravenous administration 
of two-arm PEGylated cMBP2-targeted (442/cMBP2-1PEG) or alanine control (440/Ala-
1PEG) polymers mixed with three-arm non-PEGylated polymer 689 into Huh7 tumor bearing 
mice. Luciferase gene expression is presented as relative light units per organ or tumor 
(RLU/organ). Lysis buffer RLU values were subtracted. Liver weight was around 1.6 g, lung 
weight around 230 mg and Huh7 tumor weight 452 ± 189 mg. Represented is the mean ± 
S.E.M. of five mice per group. B) Quantification of luciferase pDNA detected in tumors 4 
hours after intravenous administration of either cMBP2-targeted or alanine control single - or 
bi-polymeric particles determined with qPCR. Represented is the mean ± S.E.M. of three mice 
per group. qPCR was performed by Petra Kos (PhD student, LMU Pharmaceutical 
Biotechnology). Significance of the results was evaluated by t-test (*p<0.05).  
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lysis buffer and subsequently centrifuged. Luciferase activity determined in the supernatant 
yielded a significant cMBP2 tumor targeting effect, however with a lower luciferase expression 
in tumor and a remarkably increased expression in lung (Figure 14). 
 
 
2. Circumventing chemoresistance of cancer 
In this chapter, two different approaches to circumvent chemoresistance of cancer were 
analyzed. First, the efficacy of the drug salinomycin against cancer cells and its ability to inhibit 
migration and metastasis was investigated in vivo. These experiments were performed together 
with Florian Kopp (PhD thesis 2013, LMU). The additive effect of salinomycin to the classical 
therapeutic drug doxorubicin was further investigated in a tumor mouse model. Secondly, 
packing of chemotherapeutic drugs inside mesoporous nanoparticles was investigated in vivo 
in terms of biodistribution, biocompatibility and tumor targeting. Stefan Niedermayer (PhD 
thesis 2014, LMU) and Stefan Datz (PhD student, LMU Physical Chemistry) synthesized these 
mesoporous nanoparticles (MSN).   
Figure 14: Systemic gene transfer after co-addition of a non-shielded four-arm polymer. 
Gene expression in tumor, lung and liver 48 hours after intravenous administration of two-arm 
PEGylated cMBP2-targeted (442/cMBP2-1PEG) or alanine control (440/Ala-1PEG) polymers 
combined with four-arm non-PEGylated polymer 606 into Huh7 tumor bearing mice. 
Luciferase gene expression is presented as relative light units per organ or tumor (RLU/organ). 
Lysis buffer RLU values were subtracted. Liver weight was around 1.5 g, lung weight around 
210 mg and Huh7 tumor weight 438 ± 152 mg. Represented is the mean ± S.E.M. of five mice 
per group. Significance of the results was evaluated by t-test (**p<0.01). 
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2.1. Effects of doxorubicin upon increasing dosage 
Regarding the effect of the classical chemotherapeutic drug doxorubicin on tumor growth and 
metastasis of 4T1-Luc breast tumors different dosages were evaluated in a preliminary dose-
finding experiment for subsequent combinatorial treatment. BALB/c mice (n = 12) were 
divided into four groups, one control group (NaCl 0.9 %) and three treatment groups (2 mg/kg, 
5 mg/kg, and 8 mg/kg doxorubicin). Luciferase expressing syngeneic 4T1 breast cancer cells 
were inoculated into the mammary fat pad. 24 hours later treatment started and was repeated 
every six days for three times. On day 18, after tumor cell inoculation, two mice treated with 8 
mg/kg doxorubicin had to be euthanized due to severe weight loss (the third mouse of this group 
had to be euthanized already on day 7). The group treated with 5 mg/kg doxorubicin also lost 
weight initiating after one week of treatment compared to the control or lowest treatment group 
(2 mg/kg doxorubicin) which constantly gained weight. Figure 15 shows the weight loss-to-
time diagram. 
  
Treatment with the lowest dosage (2 mg/kg doxorubicin) mediated no effect on hampering 
tumor growth but a similar increase in tumor volume as the control group visible in a tumor 
growth curve (Figure 16-A). Only treatment with 5 mg/kg doxorubicin led to a significant tumor 
growth inhibition without premature termination due to severe medical condition (Figure 16-
B).       
Figure 15: Weight loss-to-time diagram. Weight development of mice during systemic 
treatment with 2 mg/kg, 5 mg/kg, 8 mg/kg doxorubicin or control starting with 4T1-Luc breast 
cancer cell inoculation (day 0) and ending with euthanasia (day 22, day 18 for the 8 mg/kg 
group). Represented is the mean ± S.E.M. of three (two within the 8 mg/kg treatment group) 
mice per group over time.  
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At the end of the trial on day 22 (mice treated with 8 mg/kg doxorubicin on day 18) metastasis 
formation to the lungs was evaluated via bioluminescence imaging. For this purpose mice were 
anesthetized and injected with Na-luciferin intraperitoneally. After 15 minutes of distribution 
mice were euthanized through cervical dislocation, lungs were dissected and bioluminescence 
imaging was performed. For quantification of the tumor burden bioluminescent signals were 
counted as total flux/area (photons/second/cm2). Figure 17-A represents the luminescent signal 
of 4T1-Luc tumors in lungs. The average luciferin signal in lungs of the group treated with the 
lowest dose of doxorubicin (2 mg/kg) was significantly higher than in the control group 
implying an enhanced metastasis formation upon low dosage treatment. Even higher dosage 
with 5 mg/kg doxorubicin led to a slightly increased tumor burden in the lungs compared to the 
control group. The highest dosage (8 mg/kg) of doxorubicin caused minor metastasis formation 
to the lungs. To visualize these findings, two pictures (ventral and dorsal side) were taken per 
lung (Figure 17-B). The group treated with 2 mg/kg doxorubicin had much higher luminescent 
signals than the other groups. As this experiment was performed for dose-finding, these results 
need to be validated by larger group numbers.     
 
 
Figure 16: Tumor growth over time. Tumor volume of BALB/c mice bearing 4T1-Luc breast 
tumors in the mammary fat pad during three systemic treatments (day 1, 7 and 13) with 2 
mg/kg, 5 mg/kg or 8 mg/kg doxorubicin or control (NaCl 0.9 %). Tumor growth was monitored 
for 22 days at indicated time points. A) Average tumor volumes of all four groups over time. 
B) Average tumor volumes of the group treated with 5 mg/kg doxorubicin compared to the 
control group. Significance of the results was evaluated by t-test (*p<0.05; **p<0.01).   
Represented is the mean ± S.E.M. of three mice per group.   
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2.2. Influence of salinomycin on tumor growth 
To evaluate the efficacy of the drug salinomycin to hamper tumor growth, luciferase expressing 
4T1 breast cancer cells and syngeneic BALB/c mice were used in a subcutaneous tumor model. 
Subcutaneous tumor bearing mice were treated intraperitoneally with either salinomycin (5 
mg/kg) or control (DMSO in phosphate buffered saline) for six times between day 3 and 15 
after tumor implantation. Treatment with salinomycin mediated similar tumor size increase 
Figure 17: Quantification of tumor burden in the lungs. A) The luminescent signal of 4T1-
Luc tumor formation to the lungs was counted as total flux/area (photons/second/cm2). 
Represented is the mean ± S.E.M. of three mice per group. Significance of the results was 
evaluated by t-test (*p<0.05). B) Images of the harvested lungs. Panel no. 1 shows the tumor 
burden of the lungs of the control group, no. 2 of the group treated with 2 mg/kg doxorubicin, 
no. 3 of the group treated with 5 mg/kg doxorubicin and no. 4 of the group treated with 8 mg/kg 
doxorubicin. Each lung was pictured from dorsal and ventral side.      
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over time to the control group visible in a tumor growth curve (Figure 18-A). Only a minor 
effect on tumor size could be observed for the final day (day 17) (Figure 18-B).  
 
All mice were in good general condition during the experiment and both groups showed similar 
weight increase over time (Figure 19).  
Figure 18: Tumor growth rate. Tumor volume of BALB/c mice bearing subcutaneous 4T1-
Luc breast tumors during six intraperitoneal treatments (day 3, 6, 8, 10, 13 and 15) with 5 mg/kg 
salinomycin or control. A) Average tumor volumes of both groups over time. Tumor growth 
was monitored for 17 days at indicated time points. B) Average tumor volumes of the 
salinomycin treated group compared to the control group on the final day (day 17).  
Represented is the mean ± S.E.M. of nine mice per group.     
Figure 19: Weight loss-to-time diagram. Weight development of mice during intraperitoneal 
treatment with 5 mg/kg salinomycin or control starting with 4T1-Luc breast cancer cell 
inoculation (day 0) and ending with euthanasia (day 17). Represented is the mean ± S.E.M. of 
nine mice per group over time. 
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2.3. Influence of salinomycin on tumor colonization and migration 
Besides the findings of salinomycin on hampering tumor growth we considered whether 
salinomycin is able to prevent metastasis formation in vivo. Hence, the effect of salinomycin 
on tumor cell colonization and migration was evaluated in a syngeneic 4T1-Luc mouse model. 
BALB/c mice (n = 20) were divided into two groups, one control group and one treatment 
group. Luciferase expressing syngeneic 4T1 breast cancer cells were injected intravenously via 
tail vein. 24 and 0.5 hours before tumor cell inoculation the treatment group was premedicated 
intraperitoneally with 5 mg/kg salinomycin. Treatment was repeated on day 3, 6 and 9 after 
tumor cell injection and tumor growth was monitored using bioluminescence imaging on day 
3, 8 and at the end of the experiment (day 13). For this purpose mice were anesthetized and 
injected with Na-luciferin intraperitoneally. After 15 minutes of distribution bioluminescence 
imaging was performed. One mouse of the control group had to be sacrificed already earlier 
due to severe medical condition. Figure 20 shows the luminescent signals of the 4T1-Luc 
tumors in the lungs at the end of the trial (day 13).      
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Figure 20: Bioluminescence Imaging. A) Images of mice with primary tumor formation in 
the lungs treated with control. The upper panel shows dorsoventral and the lower panel shows 
ventrodorsal images of mice. B) Images of mice with primary tumor formation in the lungs 
treated with 5 mg/kg salinomycin. The upper panel shows dorsoventral and the lower panel 
shows ventrodorsal images of mice. C) Images of dissected lungs. The upper panel shows 
tumor burden in the lungs of the control treated group and the lower panel shows tumor burden 
in the lungs of the salinomycin treated group. 
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All mice in both groups exhibited a thoracic luminescent signal reflecting the primary tumor 
burden in the lung of each mouse. A stronger signal could be observed in dorsal position of the 
mice (Figure 20-A+B lower panel). Mice treated with salinomycin showed similar signals in 
the lungs to the control mice. To localize the luminescent signal quite clearly lungs were 
dissected and imaged separately (Figure 20-C). The findings are in accordance with images of 
the living mice, salinomycin treated mice had similar signals in the lungs to control treated 
mice. 
For quantification of the tumor burden over time bioluminescence imaging was performed on 
day 3, 8 and at the end of the trial (day 13). Signals were counted as total flux/area 
(photons/second/cm2). Figure 21 represents the average luminescent signals over time. In line 
with the subcutaneous model, treatment with salinomycin did not yield a significant effect on 
primary tumor formation and growth over time. 
 
 
 
 
 
 
 
 
 
 
To evaluate the effect of salinomycin on hampering migration, metastasis formation from 
primary tumor to secondary organs was analyzed subsequently. Therefore, mice were 
euthanized at the end of the trial (day 13) and organs (brain, spleen, kidneys and liver) were 
dissected for subsequent ex vivo luciferase measurements. Organs were homogenized in cell 
culture lysis buffer followed by centrifugation and determination of the luciferase activity in 
the supernatant. Remarkably, metastases in brain, spleen and kidneys were significantly 
reduced after treatment with salinomycin (Figure 22).  
 
Figure 21: Quantification of tumor burden in the lungs. The luminescent signal of 4T1-Luc 
tumor formation in the lungs was counted as total flux/area (photons/second/cm2). Represented 
is the mean ± S.E.M. of ten (treatment group) or nine (control group) mice over time. 
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All mice were in good general condition at the beginning of the experiment. After one week 
they started to lose weight due to the tumor burden in the lungs and therefore the experiment 
had to be terminated at day 13. Both groups show similar body weight levels over time (Figure 
23). 
 
 
 
 
 
 
 
 
 
 
Figure 22: Metastasis formation in a syngeneic intravenous mouse tumor model. 
Metastasis in 4T1-Luc tumor bearing mice on day 13 after intraperitoneal treatment with 5 
mg/kg salinomycin or control. Luciferase gene expression was analyzed in brain, spleen, 
kidneys and liver. Significance of the results was evaluated by t-test (*p<0.05; **p<0.01). 
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2.4. Combinatorial effect of doxorubicin and salinomycin 
Due to the positive effect of salinomycin on hampering migration but not on tumor growth 
reduction, it´s efficacy as an additive compound to the classical chemotherapeutic drug 
doxorubicin was investigated in a syngeneic tumor mouse model. BALB/c mice (n = 40) were 
divided into four groups, one control group and three treatment groups (single doxorubicin, 
single salinomycin and combined treatment). Luciferase expressing syngeneic 4T1 breast 
cancer cells were inoculated into the mammary fat pad. 24 hours later treatment with 
doxorubicin started. As the preliminary dose-finding experiment for doxorubicin revealed 
tumor growth inhibition but also severe weight loss of mice treated with 5 mg/kg and 8 mg/kg 
a lower dosage was inescapable (Figure 15 + 16). 2 mg/kg implied enhanced metastasis 
formation and mediated no tumor growth inhibition, thus, a compromise solution was found 
favourable. The doxorubicin and combinatorial group received 3.5 mg/kg weekly for three 
weeks intravenously. The salinomycin and combinatorial group received 5 mg/kg twice per 
week intraperitoneally. Treatment with salinomycin again mediated similar tumor size increase 
over time to the control group visible in a tumor growth curve (Figure 24-A). Only treatment 
with doxorubicin could reduce the tumor burden significantly whereas the combinatorial 
treatment could not yield any additional effect on tumor growth inhibition to single doxorubicin 
treatment. In Figure 24-B a detailed illustration of tumor size proportions at the end of the trial 
(day 21) is shown.   
Figure 23: Weight loss-to-time diagram. Weight development of mice during intraperitoneal 
treatment with 5 mg/kg salinomycin or control starting with intravenous 4T1-Luc breast cancer 
cell inoculation (day 0) and ending with euthanasia (day 13). Represented is the mean ± S.E.M. 
of ten (treatment group) or nine (control group) mice over time. 
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At the end of the trial, on day 21 after tumor cell inoculation, metastasis formation to the lungs 
was evaluated using bioluminescence imaging. For this purpose mice were anesthetized and 
injected with Na-luciferin intraperitoneally. After 15 minutes of distribution mice were 
euthanized through cervical dislocation, lungs were dissected and bioluminescence imaging 
was performed. Figure 25-A shows the luminescent signals of the 4T1-Luc tumor burden in the 
lungs at the end of the trial (day 21). One mouse in the control group (number 9) and two in the 
doxorubicin treated group (number 5 and 9) did not develop metastasis formation to the lungs. 
For quantification of the tumor burden in the lungs bioluminescent signals were counted as total 
flux/area (photons/second/cm2). Mice without metastases in the lungs were excluded as the 
experimental settings malfunctioned here. The control group yielded the highest amount of 
metastases in the lungs followed by the treatment groups (Figure 25-B). Within this 
experimental setting neither single nor combinatorial treatment were able to hamper metastasis 
formation significantly.            
 
 
Figure 24:  Tumor growth over time. Tumor volume of BALB/c mice bearing 4T1-Luc breast 
tumors in the mammary fat pad during either three systemic treatments (day 1, 8 and 15) with 
3.5 mg/kg doxorubicin or six intraperitoneal treatments (day 4, 6, 11, 13, 18 and 20) with 5 
mg/kg salinomycin or a combination of both. A) Average tumor volumes of all groups over 
time. Tumor growth was monitored for 21 days at indicated time points. B) Average tumor 
volumes of all treatment groups compared to the control group on the final day (day 21). 
Significance of the results was evaluated by t-test (*p<0.05). 
Represented is the mean ± S.E.M. of ten mice per group.      
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Figure 25: Metastasis formation to the lungs. A) Bioluminescence imaging of the dissected 
lungs. Panels (from top down) show the tumor burden in the lungs of the control, single 
doxorubicin, single salinomycin and combined treated mice. Each lung was pictured from 
dorsal and ventral side. B) The luminescent signal of 4T1-Luc tumor formation to the lungs 
was counted as total flux/area (photons/second/cm2). Represented is the mean ± S.E.M. of ten 
mice per group.   
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All mice were in good general condition during the whole experiment, however the group 
treated with doxorubicin plus salinomycin showed minor weight increase over time compared 
to the other groups (Figure 26). 
 
2.5. Mesoporous silica nanoparticles (MSN) for efficient drug delivery 
Circumvention of resistance to a drug, to reduce its side effects or to protect it against body 
fluids can be achieved by encapsulating chemotherapeutics into drug delivery vehicles. Below, 
a multifunctional delivery vehicle based on mesoporous silica nanoparticles (MSN) with a pH-
responsive coating is investigated in vivo. In previous in vitro experiments, MSN were 
characterized regarding physical and chemical properties and showed the successful delivery 
of several cargo into cells (Stefan Niedermayer, Veronika Weiss, PhD theses 2014, LMU).      
2.5.1. Systemic biodistribution of MSN 
In a first experiment, the biodistribution of functionalized polymer-coated and folic acid (FA) 
targeted MSN (MSN-PVP-PEG-NH2-FA) was compared with unfunctionalized MSN (MSN-
NH2) and evaluated in tumor free mice. Anesthetized mice were injected intravenously into the 
tail vein with a 100 µg (5 mg/kg) dose of Cy7-labeled particles (Cy7 was covalently linked to 
amino-groups on the surface). Analysis using NIR imaging of the mice was done immediately 
after injection and repeated after 0.25, 0.5, 4, 24 and 48 hours. Figure 27 shows one 
representative mouse per group. Both particle types were well tolerated by the mice and both 
showed similar short circulation times. In ventral position of the mice (Figure 27 - upper panel) 
Figure 26: Weight loss-to-time diagram. Weight development of control, doxorubicin, 
salinomycin or combined treated mice starting with 4T1-Luc breast cancer cell inoculation (day 
0) and ending with euthanasia (day 21). Represented is the mean ± S.E.M. of ten mice per 
group. 
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a signal in the spleen could be observed on the left side of the body. The fluorescent signal 
cranial represents the lungs. In dorsal position (Figure 27 - lower panel) preferred liver 
accumulation could be observed. A signal in the bladder occurred 15 minutes after injection. In 
summary, both particle types showed similar biodistribution manners upon systemic 
administration.    
 
Figure 27: Biodistribution upon systemic administration. Cy7-labeled functionalized 
(MSN-PVP-PEG-NH2-FA) and unfunctionalized (MSN-NH2) particles were injected 
intravenously and NIR imaging was performed immediately. Time dependent distribution over 
48 hours. The upper panel shows dorsoventral and the lower panel ventrodorsal images of mice. 
One representative mouse per group is shown. The color scale (efficiency) had a minimum of 
1.2e-8 and a maximum of 1.0e-7 fluorescent photons/incident excitation photon.   
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To investigate the stability of particles and the attachment of the fluorescent dye due to the 
signal in the bladder, a second biodistribution experiment with Cy7 covalently linked to the 
inner surface of the particles was carried out. Anesthetized mice were injected intravenously 
into the tail vein with Cy7-loaded functionalized or unfunctionalized particles. Analysis using 
NIR imaging of the mice was done immediately after injection and repeated after 0.25, 0.5, 4, 
24 and 48 hours. Figure 28 shows one representative mouse per group. Both particle types 
showed again similar short circulation times with a generally weaker fluorescent signal intensity 
compared to particles labeled on the outside of MSN. In dorsal position (Figure 28 - lower 
panel) preferred liver accumulation and a signal in the lung could be observed. Importantly, no 
signal in the bladder is visible implying a good particle stability and a stable attachment of dye 
to particles.   
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2.5.2. Biocompatibility after systemic administration of MSN 
To test the biocompatibility of mesoporous nanoparticles and to exclude the possibility of acute 
toxic effects after single dose application clinical chemistry parameters were analyzed. Tumor 
free NMRI nude mice (n = 9) were euthanized 48 hours after intravenous administration of a 
100 µg (5 mg/kg) dose of functionalized (MSN-PVP-PEG-NH2-FA) and unfunctionalized 
Figure 28: Biodistribution upon systemic administration. Cy7-loaded functionalized 
(MSN-PVP-PEG-NH2-FA) and unfunctionalized (MSN-NH2) particles were injected 
intravenously and NIR imaging was performed immediately. Time dependent distribution over 
48 hours. The upper panel shows dorsoventral and the lower panel ventrodorsal images of mice. 
One representative mouse per group is shown. The color scale (efficiency) had a minimum of 
1.3e-8 and a maximum of 6.0e-8 fluorescent photons/incident excitation photon.   
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(MSN-NH2) particles or control (HEPES buffered glucose, HBG). Blood was collected in 
serum tubes. Serum parameters are shown in Table 1. Compared to the control group, treatment 
with both particle types showed no deviation of alanine transaminase (ALT) and aspartate 
transaminase (AST) levels implying intact liver function. Furthermore, serum creatinine levels 
and blood urea nitrogen (BUN) did not alter, proving that treatment did not compromise kidney 
function. Besides, histopathological examination of liver, lung, spleen and kidney were carried 
out. Organs were dissected, fixed in formalin, embedded into paraffin and stained with eosin 
and haematoxylin. Both particle types exhibited no histological disturbances compared to the 
HBG (control) treated group (Figure 29). 
Treatment  
group  
ALT (U/l) 
 ± SD  
AST (U/l) 
 ± SD  
Creatinine (mg/dl) 
 ± SD  
BUN (mg/dl) 
 ± SD 
control 33.9 ± 12.9 54.7 ± 14.1 0.3 ± 0.0 47.3 ± 8.5 
MSN-PVP-PEG- 
NH2 –FA 
43.2 ± 13.6 59.2 ± 12.1 0.3 ± 0.0 43.9 ± 6.7 
MSN-NH2 32.5 ± 2.5 51.9 ± 2.1 0.3 ± 0.0 47.4 ± 6.5 
 
 
 
 
 
 
 
Table 1: Clinical chemistry parameters. Values shown: alanine transaminase (ALT); 
aspartate transaminase (AST); creatinine, blood urea nitrogen (BUN). 
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2.5.2.1. Biocompatibility with increased dosages of MSN 
To test the biocompatibility of MSN with increased dosages a further experiment was carried 
out subsequently. Tumor free NMRI nude mice (n = 8) were divided into four groups and 
injected intravenously with a 1.6 mg (80 mg/kg) or 2 mg (100 mg/kg) dose of functionalized 
(MSN-PVP-PEG-NH2-FA) and unfunctionalized (MSN-NH2) particles. Intravenous 
administration of MSN was repeated after one week. Neither single nor second application of 
both dosages mediated any visual sign of toxicity. 
2.5.3. Tumor-targeting after systemic injection of MSN 
In a next step, biodistribution and tumor targeting upon systemic administration of MSN was 
investigated using confocal microscopy in a subcutaneous mouse tumor model with FA receptor 
overexpressing MDA MB 231 (breast adenocarcinoma) cells in NMRI nude mice (n = 9). 
Subcutaneous tumor bearing mice were injected intravenously via tail vein with functionalized 
but untargeted (MSN-PVP-PEG-NH2) and FA targeted (MSN-PVP-PEG-NH2-FA) particles 
Figure 29: Histopathological sections 48 hours after systemic treatment with control 
(HBG), functionalized (MSN-PVP-PEG-NH2-FA) and unfunctionalized (MSN-NH2) 
particles. a) Liver after treatment with HBG, b) functionalized MSN and c) unfunctionalized 
MSN. d) Lung after treatment with HBG, e) functionalized MSN and f) unfunctionalized MSN. 
g) Spleen after treatment with HBG, h) functionalized MSN and i) unfunctionalized MSN. j) 
Kidney after treatment with HBG, k) functionalized MSN and l) unfunctionalized MSN. One 
representative image is shown. The scale bars represent 100 µm.     
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loaded with fluorescent dyes (calcein and covalently linked ATTO 633). The control group was 
injected with HBG. After 3 hours mice were euthanized, tumors and organs (liver, lung, spleen 
and kidneys) were dissected, prepared for cryosections and stained with DAPI. Figure 30 shows 
slices of cryosections analyzed via confocal microscopy. The highest accumulation of particles, 
visible as red dots (ATTO 633), can be seen in spleen followed by liver and lung but no particles 
can be seen in kidneys. Calcein loading was not detectable presumably due to the very weak 
signal and the high autofluorescence of the tissue in the region of calcein-detection (data not 
shown). Of note, both particles also accumulate passively in tumor. The active targeting abilities 
of FA targeted particles could not be evaluated within this experimental setting and have to be 
investigated further. 
 
 
Figure 30: Distribution of MSN in a tumor mouse model. Passive tumor targeting of 
functionalized untargeted MSN-PVP-PEG-NH2 and folic acid (FA) targeted MSN-PVP-PEG-
NH2-FA after systemic injection into MDA MB 231 tumor bearing mice. Cryosections of 
tumor, liver, lung, spleen and kidney 3 hours after injection. One representative mouse per 
group is shown, one mouse per horizontal row. Cell nuclei were stained with DAPI (blue) and 
particles with ATTO 633 (red). Images were taken with 63 x magnification. The scale bar 
represents 50 µm. Slices were analyzed by Veronika Weiss (PhD student, LMU, Department 
of Chemistry). 
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2.5.4. Retention of MSN in subcutaneous tumors 
The retention efficacy of FA ligand containing MSN was investigated in a subcutaneous mouse 
tumor model with FA receptor overexpressing KB (human cervix carcinoma) cells in NMRI 
nude mice (n = 6) using NIR imaging. Subcutaneous tumor bearing mice were injected 
intratumorally with Cy7-labeled functionalized FA targeted (MSN-PVP-PEG-NH2-FA) and 
untargeted (MSN-PVP-PEG-NH2) MSN. Figure 31 shows total flux per tumor normalized to 
the initial value for one week after injection of MSN. Slightly increased retention for the FA 
modified particles could be observed within the first few hours compared to untargeted 
particles. Both particles displayed prolonged retention in tumors for more than one week 
(experiment had to be terminated as tumors became too big in size which is one of the human 
end points) compared to lower persistence upon systemic administration. 
 
Figure 31: Retention of MSN in the tumor tissue. Folic acid (FA) targeted (MSN-PVP-PEG-
NH2-FA) and untargeted (MSN-PVP-PEG-NH2) MSN labeled with Cy7 were injected 
intratumorally into KB tumor bearing mice. NIR imaging was performed for 7 days after 
application of MSN. A) Fluorescence signals of tumors were counted as total flux/area 
(photons/second/cm2) and normalized to 0 minutes (min). Represented is the mean ± S.E.M. of 
three mice per group. B) Representative images of targeted (top) and untargeted (bottom) MSN 
in tumors. 
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IV. DISCUSSION 
1. Polymeric nucleic acid carriers for tumor targeted gene delivery 
1.1. In vivo evaluation of polypropylenimine dendrimers 
In this chapter synthetic nucleic acid carriers based on the precise, symmetrical PPI dendrimer 
structure were evaluated in terms of their transfection efficacy. Modification of synthetic 
vectors while maintaining a defined structure reveals a great opportunity to overcome different 
obstacles in gene delivery. Increased molecular weight of the polymers can on the one hand 
improve transfection efficacy but on the other hand might result in increased cytotoxicity [88]. 
It is known that environment-triggered biodegradation can solve this problem [27, 89, 90]. 
Therefore, the octavalent polypropylenimine core (PPI G2) was attached with increasing units 
of small sequence-defined oligomers based on the oligoamino acid succinoyl-tetraethylene 
pentamine (Stp) [92]. Sequence-defined Stp polymers had been generated in precise form by 
solid-phase synthesis [92, 94, 162]. Biodegradability of Stp-linked PPI dendrimers results from 
reducible disulfide linkages through the incorporation of cysteines for which reason the Stp 
modified conjugates dissociate in the reducing cytosol environment (Figure 2).  
In previous in vitro experiments the PPI conjugate with 5 Stp units (536/PPI-Stp5) revealed the 
most promising characteristics for in vivo application such as high transfection efficacy, good 
pDNA binding ability, low cytotoxicity and high endosomal buffering capacity and was 
subsequently chosen for systemic in vivo experiments. A higher luciferase gene expression in 
lung and liver was obtained with unmodified PPI G2 polyplexes (Figure 6). Aggregation of PPI 
G2 polyplexes into micrometer-sized structures could lead to their accumulation and 
entrapment in lung capillaries explaining the undesirable luciferase expression in this organ 
[163, 164]. Tang et al. also showed that DNA complexes of unmodified dendrimers generally 
appear as clusters in electron micrographs and have diameters in solutions larger than 1 µm 
[165]. In contrast, the modified conjugates are smaller (about 267 nm) and could therefore have 
a better systemic distribution and accumulation in the tumor tissue due to the so called enhanced 
permeability and retention (EPR) effect [50] explaining the significantly higher tumor 
luciferase expression of the 536/PPI-Stp5 conjugates compared to the control PPI G2 
polyplexes. This promising in vivo data illustrates the conversion of unmodified Stp which is 
ineffective [166] due to its small size into potent gene carriers upon attachment to PPI. This 
concept presents a platform of several modifications for future experiments such as better 
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stabilizing [95], targeted and shielded [70] sequence-defined oligomers to further improve gene 
delivery.  
1.2. Effect on transfection efficacy in vivo upon incorporation of histidines       
Next, precise, tunable structures with multiple functional domains were generated [167, 168] 
using solid-phase synthesis with Stp and succinoyl-pentaethylene hexamine (Sph). The Sph 
building block showed an improved nucleic acid compaction and gene transfer in vitro [162] 
which is in line with our preliminary in vitro experiments yielding the most promising results 
with this structure, thus it has undergone further investigations. A bottleneck in transfection 
process after cellular uptake is the escape of polyplexes from endolysosomes to reach the 
cytoplasm. The so called “proton sponge hypothesis” postulates improved transfection results 
by cationic delivery agents with high endosomal buffering capacity [48]. The endosomal escape 
is caused by chloride and water accumulation in the endosomes leading to osmotic pressure. 
Triggered by the concomitant increase of positive polymer charges in the endosomes, vesicles 
lyse consequently and release their content into the cytosol [47]. Histidine residues become 
cationized upon protonation of their imidazole rings, thus enhancing endosomal buffering 
capacity [49].  
Polymers based on the building block Sph modified with histidines in the polycationic 
backbone (606/Sph-HC) and the histidine-free analog (608/Sph-AC) were compared with their 
transfection efficacy after intravenous administration into tumor bearing mice (Figure 8). The 
transgene expression in the Neuro2A tumor tissue 48 hours after injection was approximately 
32-fold higher with the histidinylated polymers compared to its histidine free analog, implying 
a critical impact of histidines on gene transfer. Remarkably, gene expression levels in tumors 
were higher than in lung, liver, spleen, kidney and heart in the case of the histidinylated 
polymers. Which, in fact, is in accordance with the high density of blood vessels and low 
amount of infiltrating macrophages in Neuro2A tumors [169]. These characteristics cause on 
the one hand good DNA uptake into the tumor and on the other hand low DNA degradation and 
therefore facilitate high gene expression. Expression levels in lungs were 30-fold lower than in 
tumor compared to the high molecular weight linear polyethylenimine (LPEI), a cationic 
polymer also labeled as “gold standard” for pDNA delivery, which mediates 100-fold higher 
transfection levels in lungs than in Neuro2A tumors [170]. The good toleration of the polymers 
investigated in this experiment compared with LPEI 22 kDa [88, 170] and the far lower lung 
expression are in accordance with their lower molecular weight. 
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1.3. Evaluation of targeted c-Met-directed polymers for efficient gene transfer 
in vivo 
Instead of passive targeting, another strategy to facilitate uptake of delivery agents into the 
tumor tissue is active targeting via targeting ligands. The c-Met/hepatocyte growth factor 
receptor (HGFR) is overexpressed in many tumors and hence displays an interesting target 
receptor in cancer therapy. The c-Met binding ligand cMBP2 with the amino acid sequence 
KSLSRHDHIHHH has previously been reported by Kim et al. In their study they showed 
targeting in vitro and in vivo with the radiolabeled (125I) peptide here called cMBP2 [171] and 
proved its application as a specific optical imaging system [172]. Another c-Met binding 
peptide with the amino acid sequence YLFSVHWPPLKA was already tested as radioiodinated 
diagnostic agent for tumor imaging [173]. Yet, targeting c-Met has not been applied for gene 
delivery so far. Because its superiority over the other c-Met binding peptide (Petra Kos, PhD 
thesis 2014, LMU) the cMBP2 ligand was conjugated to sequence-defined oligomers composed 
of the artificial amino acid Stp for alleviation of gene delivery, histidines for increased buffering 
capacity as described before, terminal cysteines for increased polyplex stability and 
polyethylene glycol (PEG) units for surface shielding (Scheme 1). Targeted polyplexes were 
investigated in vivo in a xenograft tumor mouse model and compared to their untargeted control.              
1.3.1. After intratumoral administration 
In the first in vivo experiments, polyplexes were injected locally into subcutaneous c-Met 
overexpressing Huh7 tumors. Here, two-arm polymers with two different amounts of PEG24 
units for surface shielding were investigated. Surface modification of delivery agents with PEG, 
a hydrophilic molecule, has been verified as a strategy to increase the solubility of hydrophobic 
drugs, prolong circulation times and reduce unspecific interactions with blood components like 
the complement system. By passive targeting it causes a higher accumulation at the tumor-site 
and can facilitate the incorporation of active targeting ligands additionally [174]. The PEG 
content has an influence on the polyplex biodistribution and the ligand accessibility but it can 
also reduce reporter gene expression [175-178].  
We demonstrated that the cMBP2-targeted polymers, regardless of the amount of PEG 
shielding (442/cMBP2-1PEG and 694/cMBP2-2PEG), showed much higher gene expression in 
tumor than their alanine control analogs (440/Ala-1PEG and 616/Ala-2PEG) (Figure 9-A) 
favoring polymers with only 1 PEG24 chain. A proof for specificity of the targeting mechanism 
is given by the structural identity of both polyplexes apart from the cMBP2 ligand.  
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To investigate the retention capability in the tumor tissue, targeted and untargeted polyplexes 
were locally injected and their elution from the tumor was followed up for several days (Figure 
10). Both particles remained in tumor over 72 hours, however, the non-targeted particles 
(440/Ala-1PEG) had a slightly shorter retention time as only a barely visible signal could be 
detected for the last time point. Moreover, a small part of these particles was immediately 
washed out of the tumor. Overall, a significantly different retention time could not be 
demonstrated within this experimental setting. One reason therefore might be the size of the 
polyplexes (approximately 200-400 nm) as they are more rigid once applied into the tumor 
tissue than smaller untargeted particles which - since unbound - can easier access the blood 
vessels and hence yield a significant retention effect [179]. 
1.3.2. After systemic administration           
Although cMBP2-targeted polymers yielded a high gene expression upon local administration, 
in most cases an intratumoral application of therapeutics cannot be considered. Hence, for 
further investigations polyplexes were applied systemically. On its way to the tumor the cargo 
has to conquer several barriers. The complex has to be stable in the blood circulation, needs 
protection from unwanted interactions with other blood components and has to avoid activation 
of the complement system [180, 181]. Therefore, polymers were equipped with PEG shielding 
domains as described above.  
In the first experiment the initial targeted and untargeted two-arm polymers were applied 
intravenously and transfection efficacy was measured after 48 hours (Figure 11). In contrast to 
the previous results upon local administration and although the amount of injected pDNA was 
increased for systemic administration, no cMBP2 targeting effect was obtained. Which, in fact, 
is underlining the special requirements and configurations of polyplexes for systemic delivery.  
Despite the application of polymers with one PEG24 chain and without disregarding the 
advantages of surface shielding, the PEG content is still very high because the polymers contain 
equal numbers of ethylene glycol units as protonatable Stp nitrogens. In a previous in vitro 
study this constitution resulted in insufficient pDNA condensation, presumably due to the 
interference with the PEG chains, and therefore form more loose structures [70]. Hence, 
polymers were designed towards the opposite direction to an augmented dimension of the 
polycationic part of the polymers. Adding extra polycationic arms has already previously been 
shown as favorable in the gene delivery process [94, 162]. Furthermore, the polycationic 
backbone of the polymers was rearranged from Stp to Sph building blocks. This replacement 
with the Sph building block was based on recent findings of improved gene transfer with this 
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novel building block [162]. Targeted and untargeted polymers now having four instead of two 
polycationic arms in the carrier backbone were applied intravenously. Although they did not 
show a beneficial effect upon in vitro transfections (Petra Kos, PhD thesis 2014, LMU), with 
these carriers a slight cMBP2 targeting effect in tumor was obtained. Tumor expression levels 
were similar to those in liver and lung (Figure 12).  
To further enhance transfection efficacy and cMBP2 tumor-targeting upon systemic 
administration, another approach in the design of polymers was considered. This time polymers 
were not directly tuned in their chemical composition, but the desired features - pDNA 
compaction plus surface shielding with targeting - were spread to two unequal sequence-defined 
polymers, one with and one without PEG24 units. As mentioned above, PEG chains can shield 
the surface but are not advantageous invariably. They presumably interfere with the pDNA 
condensation process compared to PEG-free analogous polyplexes which form a compact shape 
of rod- or toroid-like structures unlike loose “spaghetti-type” structures which were formed by 
polyplexes with PEG units [70]. Thereupon, the initial targeted two-arm polymer (442/cMBP2-
1PEG) was mixed with a non-shielded three-arm polymer (689) in a ratio of 70:30. This 30 
percent co-addition of non-shielded polymers revealed change in shape to round-shaped 
particles compared to rather spaghetti-like structures obtained before (Dr. Petra Kos, Dr. 
Markus Döblinger, LMU, unpublished data not shown). These bi-polymeric particles greatly 
enhanced gene transfer in the tumor tissue in sharp contrast to mono-polymer 442/cMBP2-
1PEG polyplexes (Figure 13-A+B).  
Despite these results we were interested whether this beneficial effect is specific to the co-added 
polymer 689 or whether it can be achieved by any non-shielded polymer. Instead of the three-
arm polymer with Stp building blocks in the carrier backbone, now the four-arm polymer with 
Sph building blocks (606) was mixed with the initial shielded and targeted two-arm polymer 
(442/cMBP2-1PEG) in the same ratio as before (30:70) and was applied intravenously. This 
time, a significant tumor targeting effect was achieved again but was associated with an 
increased gene transfer in the lung (Figure 14) stating that non-shielded polymers cannot be 
added arbitrarily. To improve gene transfer polymers have to be carefully selected and refined 
for special requirements of systemic in vivo application which obviously cannot always be 
identified by sole in vitro testing.          
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2. Circumventing chemoresistance of cancer 
2.1. Salinomycin as a potential additive compound to hamper metastasis 
Chemoresistance of cancer is a major drawback in the successful treatment of cancer patients. 
An important mechanism of resistance formation to chemotherapeutic drugs are cancer stem 
cells (CSCs). These cells within a tumor are able to self-renew after chemotherapy and are 
therefore responsible for relapse [101, 102]. Salinomycin was recently found to selectively 
target CSCs [122]. In this work it was analyzed whether this novel anticancer drug has an 
influence on tumor growth and tumor metastasis in vivo in a syngeneic mouse model. Murine 
4T1-Luc breast cancer cells originating from BALB/c mice are stably expressing luciferase 
which enables tracking of tumor growth and tumor cell dissemination via bioluminescence 
imaging.  
First, a tumor mouse model using the classical drug doxorubicin was established for subsequent 
combinatorial treatment with salinomycin. Here, a dosage needed to be found that is high 
enough to mediate a cytotoxic effect but low enough to leave some expansion space for 
beneficial effects of a combinatorial treatment. Thus, three different dosages of doxorubicin (2 
mg/kg, 5 mg/kg and 8 mg/kg) were evaluated regarding their compatibility, tumor growth and 
metastasis formation to a new tissue which was primarily the lungs (Figure 15, 16, 17). 4T1 
breast cancer cells were inoculated orthotopically into the mammary fat pad of BALB/c mice 
within this tumor model and metastasis formation was monitored. The highest dosage led to 
severe weight loss therefore the mice had to be euthanized ahead of time. 5 mg/kg doxorubicin 
revealed tumor growth inhibition but also severe weight loss thus the dosage was still too high. 
The lowest dosage mediated no tumor size reduction but, of note, implied an enhanced 
metastasis formation to the lungs instead of an expected inhibition. However, these results have 
to be validated by larger group numbers. Doxorubicin is inducing cytostatic effects as well as 
dose dependent cancer cell migration by activating TGFβ signaling as shown by 
Bandyopadhyay et al. TGFβ signaling is known to induce epithelial to mesenchymal transition 
(EMT) [182]. EMT, a developmental program leading to invasive and migratory properties of 
cancer cells, is also able to generate stem cell-like cells resulting in resistance to chemotherapy 
[103, 104].  
The CSCs targeting drug salinomycin was first tested regarding its effect on reducing tumor 
growth in vivo. Thus, a simplified setup with subcutaneous 4T1-Luc tumors in the flanks of the 
mice was used. Gupta et al. showed tumor size reduction of SUM159 human breast tumors in 
NOD/SCID mice with daily intraperitoneal injections of 5 mg/kg salinomycin for 5 weeks 
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[122]. In our tumor growth experiment treatment of 4T1-Luc tumors with salinomycin only 
mediated a minor effect on tumor size on the final day (Figure 18). We injected the same amount 
of salinomycin intraperitoneally but only for six times between day 3 and 15 after tumor 
implantation. 4T1-Luc tumors become necrotic after that short period although they were less 
than 600 mm3 in size when the experiment had to be terminated to guarantee proper results for 
further in vitro experiments and to keep the mice in a good general condition. Dosage and 
treatment intervals were not increased as the mice turned out to be apathetic for a couple of 
hours after injection of salinomycin which could be based on the recently described neurotoxic 
side effects [183]. Another issue of 4T1-Luc tumors is their poor blood supply what could also 
explain the minor effect on tumor size reduction as only a smaller amount of salinomycin is 
able to reach the tumor. Subsequent in vitro investigation of tumors revealed increased 
apoptosis, an increased miR-200c expression, elevated E-cadherin protein levels and an 
epithelial-like tumor after salinomycin treatment. Hence, treatment led to an induction of 
mesenchymal to epithelial transition (MET) (Florian Kopp, PhD thesis 2013, LMU).  
Based on these results and on encouraging preliminary in vitro experiments showing inhibitory 
effects of salinomycin on cell migration (Florian Kopp, PhD thesis 2013, LMU) we were also 
interested whether salinomycin was able to prevent metastasis in vivo. Because CSCs have been 
proposed to be in charge of colonization at secondary organs upon metastatic spreading [184] 
the question came up whether the inhibition of CSCs by salinomycin was accompanied by 
reduced metastasis formation in vivo. In this experiment 4T1-Luc cells were injected 
intravenously to specifically examine the final steps of metastasis, thus they form primary 
tumors almost without exception in the lungs. Mice were treated with salinomycin also before 
tumor cell inoculation to imitate a treated primary tumor aiming to prevent metastasis 
formation. This colonization experiment was terminated already on day 13 after tumor cell 
injection as mice started to lose weight due to the pulmonary tumor burden. Besides, this period 
was long enough to measure the luciferase signal through bioluminescence imaging (Figure 20, 
23). One mouse of the control group had to be euthanized already earlier due to severe central 
nervous disorders what later turned out to be a matter of brain metastases. Primary tumor 
formation and growth in the lungs was not significantly affected with salinomycin treatment as 
also observed in the subcutaneous tumor growth model (Figure 21). In contrast, Gupta et al. 
showed a 4-fold reduction of lung tumor burden three weeks after intravenous injection of 4T1 
cells into BALB/c mice. However, they pretreated 4T1 cells for four days in vitro with 
salinomycin compared to compound treatment of mice in our experiment, for which reason a 
direct comparison is very difficult [122]. Subsequent in vitro analysis of lung tumors revealed 
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considerably elevated miR-200c levels according to the subcutaneous 4T1-Luc tumors treated 
with salinomycin (Florian Kopp, PhD thesis 2013, LMU). Remarkably, metastases in brain, 
spleen and kidneys were significantly reduced after treatment with salinomycin determined by 
ex vivo luciferase measurements (Figure 22). These results suggest that salinomycin is capable 
to induce MET leading to significantly decreased metastasis formation to secondary organs. In 
summary, salinomycin treatment causes less migratory capacity of tumor cells, less metastasis 
and higher susceptibility to classical chemotherapy due to the induction of MET.  
Therefore, salinomycin as a drug targeting CSCs might be an interesting candidate for 
combinatorial therapies together with agents targeting non-CSCs within tumors specifically as 
tumors contain different cellular phenotypes. Oak et al. demonstrated efficient killing of HER2 
positive cells and CSCs upon treatment with the anti-HER2 monoclonal antibody trastuzumab 
and salinomycin opening an interesting possibility for further combinatorial treatments with 
salinomycin [185]. Kim et al. proposed an increased sensitivity of cancer cells to the apoptotic 
effects of doxorubicin associated with an increased DNA damage upon treatment with 
salinomycin in vitro [186]. Thus, the efficacy of salinomycin as an additive compound to the 
classical chemotherapeutic drug doxorubicin, an anthracycline antibiotic intercalating DNA, 
was investigated in the previously established syngeneic tumor mouse model. Based on those 
results of the dose finding experiment we decided to apply 3.5 mg/kg doxorubicin, the dosage 
of salinomycin was maintained with 5 mg/kg. 4T1-Luc cells were inoculated into the mammary 
fat pad and 24 hours later treatment with doxorubicin started and was repeated once a week 
compared to every six days in the preliminary experiment. These settings were changed with 
regard to the combinatorial treatment with salinomycin. Due to the slight toxic effect upon 
application of this drug we wanted the mice to recover completely before treatment with 
doxorubicin, thus the treatment intervals had always been the same. Combinatorial treatment 
with salinomycin and doxorubicin did not yield beneficial effects on tumor growth reduction. 
Only doxorubicin reduced the tumor burden significantly upon both single and combinatorial 
application (Figure 24). At the end of the trial metastasis formation to the lungs was again 
evaluated using bioluminescence imaging. Of note, some mice did not develop metastasis 
formation to the lungs implicating the problems of metastasis models. One reason could be an 
inhomogeneous inoculation of tumor cells into the mammary fat pad and into unequal areas 
more or less vascularized. On the contrary, intravenous injection of tumor cells led to a 
homogeneous colonization in the lungs within all mice implicating an advantage over the 
intramammary tumor model with spontaneous metastasis. Mice without metastases in the lungs 
were excluded from the analysis but this time neither single nor combinatorial treatment could 
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hamper metastasis formation significantly (Figure 25). However, different pharmacological 
parameters within the intramammary tumor model compared to the intravenous tumor model 
have to be considered. In future experiments the dosage of doxorubicin could be changed since 
this has a high impact on displaying beneficial effects with other compounds and the beginning 
of salinomycin treatment could be preponed to refine its effects. Despite these results 
salinomycin is still an interesting candidate for combinatorial treatments with other drugs. 
Besides, further in vitro processing still has to be performed. However, these findings illustrate 
once more the complexity of in vivo experiments and their implementation. Consequently, the 
experimental setups for further metastasis experiments should be revised and new tumor models 
should be considered such as further cancer cell lines. 
2.2. Efficacy of mesoporous nanoparticles as tumor targeted delivery agents 
circumventing chemoresistance     
A major drawback in the cure of cancer remains the multiple drug resistance (MDR) to free 
chemotherapeutic drugs and the severe toxic side effects of free chemotherapeutics to normal 
tissues due to the lack of tumor-selectivity [140]. Mesoporous nanoparticles are expected to 
overcome these obstacles by reversing MDR. Thus, a developed multifunctional drug delivery 
vehicle based on a mesoporous silica core with a pH-responsive polymer coating was 
investigated in vivo in terms of biodistribution, biocompatibility and tumor targeting.  
First, the biodistribution of mesoporous silica nanoparticles (MSN) functionalized with the 
PVP/PEG coating and the folic acid (FA) ligand was evaluated and compared to 
unfunctionalized MSN without coating. Within the first trial the fluorescent dye Cy7 was 
covalently linked to the amino-groups on the outside of the particles. Near infrared fluorescence 
imaging revealed a sufficient signal with 5 mg/kg MSN and preferred accumulation of both 
particle types in liver and spleen (Figure 27). These results are in line with similar findings 
made by Wu et al., who investigated biodistribution of MSN for the first time by magnetic 
resonance imaging (MRI) and found an accumulation in liver and spleen [187]. This 
accumulation in healthy tissues can enhance side effects, should be substantially reduced and 
the accumulation in tumor maximized. Modification of the surface with PEG can reduce uptake 
of MSN by the reticuloendothelial system (RES) and increase the blood circulation time [188, 
189]. Though this could not be observed within our experiment, dependance on amount, density 
and length of PEG has to be considered [190]. He et al. investigated in vivo biodistribution of 
MSN with several particle sizes (80 - 360 nm) and the effect of PEGylation and observed that 
MSN and PEG-MSN both mainly accumulate in liver and spleen and a minority in lung whereas 
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MSN in the size of 360 nm were easier captured by the organs [191]. The biodistribution of our 
PVP/PEG coated MSN are comparable with other studies published to date which mainly 
observe accumulation in spleen and liver. Although no clear effect upon PVP/PEG coating 
could be demonstrated within these experimental settings, particle size, shape and surface 
modification can affect biodistribution kinetics [191]. We could observe a signal in the bladder 
occurring 15 minutes after injection (Figure 27) what raised the question about the excretion of 
the particles. Degradation and elimination of MSN are investigated in many studies, but the 
wide variety not only of the particles itself but also of study designs and lack of standardization 
makes a comparison quite difficult. The porous structure and thus the large surface area of MSN 
are beneficial for accelerating degradation, but their chemical stability is generally higher than 
for organic particles [131] and the in vivo long-term effect of non-degraded particles is still 
unknown. Renal elimination of intact MSN through urine has been reported [192, 193] although 
their particle size is beyond the renal cut off limit of 4.5 - 5 nm [194], but the exact excretion 
process remained unclear in this case. Another elimination route of MSN is hepatobiliary 
excretion which has been shown by Lu et al [195]. This demonstrates the exceptional diversity 
of several MSN and their behavior meaning that unification could be beneficial for future 
experiments. Due to the bladder signal we wanted to investigate the stability of particles and 
the attachment of the fluorescent dye to the outer surface. Therefore, a second experiment was 
carried out with Cy7 linked to the inner surface of MSN. This time no bladder signal occurred 
implying a good particle stability in the blood circulation and a stable attachment of dye to 
particle although the signal intensity was lower compared to the attachment outside (Figure 28).  
To evaluate the biocompatibility of these MSN and to exclude the possibility of acute toxic 
effects after single dose application clinical chemistry parameters were analyzed. Compared to 
the control group, single treatment with functionalized (MSN-PVP-PEG-NH2-FA) and 
unfunctionalized (MSN-NH2) particles showed no deviations from liver and kidney parameters, 
(Table 1) and histopathological examinations showed no disturbances (Figure 29). Increased 
dosage with 80 and 100 mg/kg mediated no visual toxic effects. These findings are in 
accordance with He et al., they observed no tissue toxicity for MSN and PEG-MSN in one 
month [191]. Nevertheless, synthesis, particle size, morphology, surface modification, dosage 
and administration routes play an important role in hematological and histological 
biocompatibilities of MSN and have to be considered carefully. In addition, there are still many 
unknown issues that have to be addressed in the future like neuro-, brain- and reproductive 
toxicity or long term safety for up to one year [131]. 
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Targeting of nanoparticles to the tumor can be achieved by the EPR effect as mentioned earlier 
and enhanced with specific interactions between the nanoparticle and the cancer cell via active 
targeting using specific targeting ligands. Folic acid (FA) is one of the most studied targeting 
ligands for active targeting by MSN in vivo. Many tumor types possess an overexpression of 
folate receptors [64, 196] but its expression on normal tissue is limited [65], therefore folate 
receptor targeting is a frequently used model. Mamaeva et al. showed active folate receptor 
targeting with MSN after intratumoral and intravenous administration [197] and Lu et al. 
demonstrated successful tumor growth inhibition of pancreatic tumors with camptothecin 
loaded and FA modified MSN [193]. Due to their pH-responsive polymer coating, which 
enables controlled drug release, biodistribution and tumor targeting upon systemic 
administration of MSN with and without FA ligand was investigated in a subcutaneous mouse 
tumor model with folate receptor overexpressing MDA MB 231 tumors. Confocal microscopy 
of cryosections 3 hours after intravenous administration revealed again high accumulation in 
spleen and liver but also an accumulation in tumor for both MSN, presumably due to the EPR 
effect in this tissue (Figure 30). The active targeting abilities of FA targeted particles have to 
be evaluated further with quantitative measurements or chemotherapeutic drug loaded MSN.  
To evaluate the retention time of FA targeted and untargeted MSN, they were injected locally 
into subcutaneous KB tumors as these are highly overexpressing the folate receptor and were 
monitored for one week. The results display just a slightly increased retention time for the FA 
modified particles within the first few hours compared to untargeted particles (Figure 31). This 
could be due to the large size of the particles because they cannot be washed easily out of the 
tumor as it has been shown for smaller nanoparticles [179] in the same tumor model. Both 
particles showed prolonged retention times in tumor for more than one week compared to lower 
persistence upon systemic administration making them attractive also for local applications 
with constant release of drugs. The experiment had to be terminated as tumors became too big 
in size, which is one of the human end points, thus it could not be exactly defined how long the 
particles remained there.  
In conclusion, the PVP/PEG coated MSN are promising particles for tumor targeted drug 
delivery but have to be refined concerning biodistribution and circulation times. Further 
experiments regarding the loading of drugs and their controlled release still have to be 
performed in the future.      
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V. SUMMARY 
The high morbidity and mortality caused by cancer represents an urgent need to improve 
treatment of cancer patients. Insufficient success rates, side effects, therapy resistance and 
metastasis formation remain major drawbacks in the cure of cancer, despite of several treatment 
options. Therefore, we focused on two approaches to improve cancer treatment - tumor targeted 
nucleic acid delivery and prospects to circumvent chemoresistance. 
Nucleic acid therapy shows great promise for the treatment of a broad range of genetically-
based diseases. However, appropriate delivery of genes to target cells requires efficient delivery 
agents and displays a major challenge, hence three polymeric carriers were tested in vivo. First, 
the efficacy of biodegradable modified gene carriers was investigated. We could demonstrate 
that 536/PPI-Stp5 carriers with a higher molecular weight led to enhanced transfection efficacy 
in tumor and reduced gene transfer in the healthy organs lung and liver compared to unmodified 
polypropylenimine dendrimers of the second generation (PPI G2). Secondly, escape from 
endosomes is a major challenge in gene delivery. Histidines are known to improve endosomal 
escape because they increase buffer capacity. Accordingly, in vivo transfection efficacy of 
polymers enriched with histidines was compared to a histidine free analog. This histidinylation 
led to an improved gene transfer in tumor which demonstrates the beneficial incorporation of 
such functional domains. Thirdly, active targeting via targeting ligands facilitates uptake of 
delivery agents into the tumor tissue. We demonstrated targeting of c-Met/hepatocyte growth 
factor receptor (HGFR), overexpressed in many tumors, using the c-Met binding peptide 
cMBP2 as targeting ligand. After intratumoral injection targeted polyplexes, regardless of the 
amount of PEG shielding, revealed high luciferase expression in tumor demonstrating the 
specificity of the targeting mechanism. For systemic application however, polymers with an 
augmented dimension of the polycationic part had to be formulated to mediate a slight targeting 
effect in distant tumors. A mixture of the targeted and shielded polymer with a non-shielded 
polymer, a new form of pDNA polyplex, resulted in successful systemic gene transfer. These 
results show that different requirements upon systemic application have to be fulfilled to obtain 
efficient gene carriers. 
Acquisition of resistance to classical chemotherapeutics and formation of metastasis to 
secondary tissues remain enormous obstacles in the treatment of cancer. Cancer stem cells 
(CSCs) represent an important mechanism of chemoresistance and are known to be involved in 
tumor invasion and metastasis formation. Thus, the drug salinomycin, which was recently found 
to selectively target CSCs, is of particular importance for the search of new anticancer drugs. 
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Treatment with salinomycin resulted in significantly reduced metastatic tumor burden in a 
syngeneic mouse model. Concerning its effect on hampering tumor growth, salinomycin was 
not able to reduce the size of the tumor significantly. However, these findings suggest a 
combinatorial treatment with a classical chemotherapeutic drug. Therefore, we investigated the 
effect of treatment with doxorubicin and salinomycin on tumor growth and metastasis 
formation. Within our experimental settings we could not demonstrate a beneficial effect of 
salinomycin, yet we assume that the final outcome is associated with experimental setups.  
Multiple drug resistance might be overcome by packing of drugs into nanoparticles. In this field 
mesoporous silica nanoparticles (MSN) are highly promising. Controlled drug release is a 
crucial point, therefore we evaluated pH-responsive coated MSN in vivo in terms of 
biodistribution, biocompatibility and tumor targeting. MSN, regardless of coating, revealed 
preferred liver and spleen accumulation but mediated no toxic side effects after single lower 
and repeated high dosage application. MSN accumulated passively in tumors to moderate extent 
after systemic injection and showed prolonged retention after local application. 
In conclusion, this work deals with the in vivo evaluation of polymeric nanocarriers and 
strategies to circumvent chemoresistance. The results display encouraging options to improve 
cancer treatment which are a point of origin for further investigations.  
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VI. ZUSAMMENFASSUNG 
Aufgrund der durch Krebs verursachten hohen Erkrankungshäufigkeit und Todesrate bedarf die 
Therapie von Krebspatienten einer dringenden Verbesserung. Unbefriedigende Erfolgsquoten, 
Nebenwirkungen, Therapieresistenzen und Metastasenbildung stellen trotz vielfältiger 
Therapiemöglichkeiten große Hindernissse im Kampf gegen den Krebs dar. Aus diesem Grund 
haben wir uns auf zwei Herangehensweisen konzentriert. Diese sind zum einen der 
zielgerichtete Transport therapeutischer Nukleinsäuren in den Tumor und zum anderen 
Aussichten die Bildung von Chemotherapeutika-Resistenzen zu umgehen. 
Die Anwendung therapeutischer Nukleinsäuren ist sehr vielversprechend für eine große Anzahl 
an Krankheiten, die ihren Ursprung auf genetischer Ebene haben. Jedoch stellt der Transport 
von Genen in die Zielzellen eine der größten Herausforderungen dar. Hierfür werden effiziente 
Träger benötigt, weshalb wir drei verschiedene aus Polymeren bestehende Genfähren 
tierexperimentell getestet haben. Zuerst wurde die Wirksamkeit eines modifizierten, natürlich 
abbaubaren Trägers untersucht. Hierbei konnten wir zeigen, dass der Träger 536/PPI-Stp5 mit 
einem erhöhten Molekulargewicht im Vergleich zu einem unmodifizierten Polypropylenimin 
aus der zweiten Generation (PPI G2) eine erhöhte Transfektionsrate in den Tumorzellen und 
einen reduzierten Gentransfer in den gesunden Organen Lunge und Leber bewirkte. Zweitens 
stellt das Entkommen der Genfähren aus dem Endosom eine weitere Herausforderung dar. 
Histidine sind bekannt dafür dieses Entweichen zu verbessern indem sie die Pufferkapazität 
erhöhen. Aus diesem Grund wurde die Wirksamkeit von mit Histidinen ausgestatteten 
Polymeren untersucht und mit Histidin-freien Analoga verglichen. Diese Histidinylierung 
führte zu einem verbesserten Gentransfer im Tumor, wodurch der Vorteil solch funktioneller 
Domänen dargestellt werden konnte. Drittens erleichtert aktives Ansteuern von Tumorzellen 
mithilfe von Liganden die Aufnahme der Genfähren. Unter Verwendung des Liganden c-Met-
bindendes Peptid, cMBP2, steuerten wir den c-Met/Hepatozyten Wachstumsfaktor Rezeptor 
(HGFR) an, welcher in vielen Tumoren überexprimiert ist. Die Injektion der zielgerichteten 
Polyplexe in den Tumor führte ungeachtet der Höhe an Abschirmung mit PEG zu einer hohen 
Expression an Luciferase, wodurch die spezifische Wirkungsweise bewiesen werden konnte. 
Um einen zumindest leichten zielgerichteten Effekt nach systemischer Verabreichung zu 
erhalten wurden jedoch Polymere mit erhöhtem polykationischen Anteil benötigt. Erst eine 
Mischung aus zielgerichtetem abgeschirmten und nicht abgeschirmten Polymer, also eine neue 
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Art von pDNA Polyplex, führte zum Erfolg. Diese Ergebnisse machen die unterschiedlichen 
Anforderungen an eine Genfähre für die systemische Verabreichung deutlich. 
Der Erwerb von Resistenzen gegenüber klassischen Chemotherapeutika und die Metastasierung 
in sekundäre Organe stellen immer noch gewaltige Hürden im Kampf gegen den Krebs dar. 
Krebsstammzellen verkörpern einen wichtigen Mechanismus der Chemoresistenz- Bildung und 
sind an Tumorinvasion und Metastasierung beteiligt. Aus diesem Grund ist Salinomycin, ein 
Medikament welches neulich als Krebsstammzell-spezifisch entdeckt wurde, von großem 
Interesse für die Suche nach neuen Krebstherapeutika. Die Behandlung mit Salinomycin führte 
zu einer erheblich reduzierten Tumor-Metastasierung in einem gen-identischen Mausmodell, 
ohne einen wesentlichen Einfluss auf das Tumorwachstum zu haben. Diese Erkenntnisse 
rechtfertigten eine kombinatorische Behandlungsstrategie mit einem klassischen 
Chemotherapeutikum. Daraufhin haben wir die Auswirkungen auf Tumorwachstum und 
Metastasierung nach kombinatorischer Behandlung mit Doxorubicin und Salinomycin 
untersucht. Wir konnten allerdings keine vorteilhafte Wirkung durch Salinomycin erreichen. 
Jedoch vermuten wir, dass das Ergebnis mit den Versuchsbedingungen zusammenhängt. 
Die Mehrfachresistenz kann möglicherweise mithilfe der Verpackung von Medikamenten in 
Nanopartikel überwunden werden. Mesoporöse Nanopartikel aus Siliziumdioxid haben sich als 
sehr vielversprechend erwiesen. Die kontrollierte Medikamentenfreisetzung ist entscheidend, 
deshalb haben wir Partikel mit einer pH-abhängigen Hülle bezüglich ihrer Biodistribution, 
Verträglichkeit und Tumor-Ansteuerung getestet. Die Partikel zeigten unabhängig von ihrer 
Hülle eine bevorzugte Ansammlung in Leber und Milz und verursachten keine 
Nebenwirkungen sowohl nach einmaliger niedriger und zweimaliger Verabreichung einer 
höheren Dosis. Außerdem häuften sie sich nach systemischer Verabreichung in moderatem 
Umfang passiv im Tumor an und verweilten nach lokaler Verabreichung für längere Zeit im 
Tumor. 
Zusammenfassend handelt diese Arbeit von der in vivo Testung von auf Polymeren basierenden 
Genfähren und Strategien zur Umgehung von Chemoresistenzen. Die Ergebnisse zeigen 
vielversprechende Ansätze zur Verbesserung der Krebstherapie auf, welche Ausgangspunkte 
für fortführende Untersuchungen darstellen.       
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VIII. APPENDIX 
1. Abbreviations 
ABC Adenosine triphosphate (ATP) binding cassette 
Ala Alanine 
ALT Alanine transaminase 
AST Aspartate transaminase 
BCRP Breast cancer resistance protein 
BUN Blood urea nitrogen 
CCD Charge-coupled device 
cMBP2   c-Met binding peptide 2 
CMV    Cytomegalovirus 
CSCs Cancer stem cells 
Cy7 Cyanine 7 
DAPI    4`,6-diamidino-2-phenylindole 
DMSO   Dimethyl sulfoxide 
DNA    Deoxyribonucleic acid 
e.g. exempli gratia (for example) 
EDTA Ethylenediamine tetraacetic acid 
EGF    Epidermal growth factor 
EMT Epithelial to mesenchymal transition 
EPR effect   Enhanced permeability and retention effect 
FA    Folic acid 
FCS    Fetal calf serum 
FDA    Food and drug administration 
FELASA Federation of European laboratory animal science associations 
h hours 
HA2 Hemagglutinin subunit 2 
HBG    HEPES buffered glucose 
HEPES   N-(2-hydroxyethyl) piperazine-N`-(2-ethanesulfonic acid) 
HER2 Human epidermal growth factor 2 
HGF    Hepatocyte growth factor 
HGFR    Hepatocyte growth factor receptor 
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LPEI    Linear polyethylenimine 
Luc Luciferase 
MDR Multiple drug resistance 
MET Mesenchymal to epithelial transition 
min minutes 
miR-200c micro RNA 200c 
miRNA micro RNA 
MRI Magnetic resonance imaging 
mRNA   Messenger RNA 
MRP1 MDR-associated protein 1 
MSN Mesoporous silica nanoparticles 
Mw    Molecular weight 
N/P Polymer nitrogen to nucleic acid phosphate ratio 
NaCl Sodium chloride 
NIR Near infrared 
NLS Nuclear localization signal 
no. Number 
NPC Nuclear pore complex 
PAMAM   Polyamidoamine 
PBS    Phosphate buffered saline 
pCMVLuc Plasmid encoding firefly luciferase under the control of CMV 
promotor 
pDNA Plasmid DNA 
PEG Polyethylene glycol 
PEG24 Polyethylene glycol with 24 ethylene glycol units 
PEI Polyethylenimine 
P-glycoprotein Permeability glycoprotein 
PLL Polylysine 
PPI G2 Polypropylenimine of the second generation 
PPI Polypropylenimine 
PVP Poly(vinylpyridine) 
RES Reticuloendothelial system 
RISC RNA-induced silencing complex 
RLU Relative light units 
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RNA Ribonucleic acid 
ROI Region of interest 
RT-PCR Reverse transcription polymerase chain reaction 
S.D. Standard deviation 
S.E.M. Standard error of the mean 
SCID Severe combined immune deficiency 
siRNA Small interfering RNA 
Sph Succinoyl-pentaethylene hexamine 
Stp Succinoyl-tetraethylene pentamine 
TAT peptide Transactivator of transcription of human immunodeficiency 
virus, a cell-penetrating peptide 
TGFβ Transforming growth factor beta 
Wnt Wingless-related integration site 
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